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ABSTRACT
The mammalian gastrointestinal mucosa regenerates dynamically throughout the lifetime,
although the complex structure is established already during embryonic development.
Gastrointestinal stem cells provide the epithelium with replicating progenitors that give
rise to the constantly renewing epithelium. The multipotent precursors are committed to a
specific cell lineage to differentiate and gain features and functions characteristic of a
particular specialized gastrointestinal cell type. Tissue renewal can also be observed, albeit
at a less rapid pace, in the liver. The balance between epithelial rejuvenation and cell death
requires a delicately orchestrated network of multiple regulatory pathways. The factors
determining cell fate and overall cell lifespan remain largely unidentified.
Inflammation hinders the regulatory cascades of the gastrointestinal tissue and may injure
the protective epithelial barrier. Characteristic of chronic intestinal inflammation is an
active stem cell-containing proliferative compartment, that is enhanced by epithelial repair
mechanisms. However, apoptosis is induced as well. In normal hepatic regeneration,
hepatocytes are able to re-enter the cell cycle and undergo limited proliferation. In severe
damage, hepatocyte-originated renewal is insufficient. Therefore, the more potent hepatic
stem cells, the ovalocytes, are activated. Both in the gastrointestinal tract and in the liver
parenchyma, the vigorous activation of stem cells due to constant epithelial damage may
lead to uncontrolled cell proliferation, and further, to cancer.
Pathogenesis of the gastrointestinal and hepatic inflammation and tumorigenesis are likely
to involve multiple different molecular pathways, including transcription factors. GATA-
4, GATA-5, and GATA-6 belong in a zinc finger protein family that regulates cell
proliferation and differentiation in many mammalian organs, including those of
endodermal origin. In mice, lack of GATA-4 or GATA-6 leads to defective endodermal
development and cell differentiation. All three endodermal GATA factors are involved in
the regulation of intestine- and liver-specific genes. Although GATA factors are closely
related to tumorigenesis in several organs, in the digestive system their role in
inflammation and tumor-related molecular pathways remains unclear.
In this study, we determined the expressions of GATA-4, GATA-5, and GATA-6 in the
human and murine gastrointestinal tract and liver during normal postnatal development, in
gastrointestinal inflammation, and finally in tumors. While GATA-4 has recently been
proposed to mediate TGF-? signaling in other tissues, we aimed to determine GATA
expression in conditions with an enhanced TGF-?/Smad pathway, such as in inflammatory
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bowel disease. Furthermore, we investigated the role of GATA proteins in the regulation
of intestine-specific and apoptosis-related factors [Fatty acid binding protein (FABP), Bcl-
2, and sucrase-isomaltase]. We also explored GATA interaction with the suggested
cofactors Friends of GATA (FOG), the cooperators hepatocyte nuclear factors (HNFs),
and the possible downstream factors Indian Hedgehog (Ihh) and erythropoietin (Epo) to
shed further light on the regulatory cascades involved in gastrointestinal and hepatic
function. Most of the results are based on expression data obtained by mRNA in situ
hybridization and immunostaining of tissues. Functional studies were carried out in human
cell lines and analyzed by RT-PCR or Western blot.
The results indicated distinct expression patterns for GATA-4, GATA-5, and GATA-6 in
the human and murine gastrointestinal tract and liver and a cooperative function with
HNF-1? and with each other in the regulation of Fabp. GATA-4 was confined to the
proximal gut, whereas GATA-5 was present only in suckling murine intestines, suggesting
an association with postnatal enzymatic changes. Interestingly, GATA-4 was absent from
the colon, but was upregulated in bowel inflammation, probably due to enhancement of
the TGF-? pathway. In gastrointestinal tumors, GATA-4 was restricted to benign
neoplasias of the stomach, while GATA-6 was detected especially at the invasive edges of
malignant tumors throughout the gut. Investigation of hepatic tumorigenesis revealed that
GATA-4, which is normally confined to embryonic hepatocytes, is upregulated in
pediatric hepatic tumors concomitantly with FOG-1 and Epo, the elevation of which was
detected also in the sera of tumor patients. Furthermore, GATA-4 was enhanced in areas
of vigorous hepatic regeneration in pediatric patients with tyrosinemia type I.  These
results suggest a central role for GATA-4 in pediatric tumor biology of the liver.
To conclude, GATA-4, GATA-5, and GATA-6 are associated with normal gastrointestinal
and hepatic development and regeneration. The appearance of GATA-4 along with TGF-
?-signaling in the inflammatory bowel, shown for the first time here, suggests a protective
role in the response to inflammation-related epithelial destruction. However, in extremely
malignant pediatric liver tumors, GATA-4 function is unlikely to be tumor-suppressing,
probably due to the nature of the very primitive multipotent tumor cells. GATA-4, along
with its possible downstream factor Epo, could be utilized as novel hepatic tumor markers
to supplement the present diagnostics. They could also serve a function in future
biological therapies for aggressive pediatric tumors.
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ABBREVIATIONS
AFP ?-fetoprotein
BMP Bone morphogenetic protein
Cdk Cyclin-dependent kinase
Cdx Caudal-related homeobox transcription factor
CKI Cyclin-dependent kinase inhibitor
DNA Deoxyribonucleic acid
E Embryonic day
Epo Erythropoietin
FABP Fatty acid binding protein
FABPL Liver fatty acid binding protein
FGF Fibroblast growth factor
FOG Friends of GATA
GATA Transcription factor binding to a “GATA” sequence
HCC Hepatocellular carcinoma
HGF Hepatocyte growth factor
HNF Hepatocyte nuclear factor
IBD Inflammatory bowel disease
IGF Insulin-like growth factor
Ihh Indian Hedgehog
IL Interleukin
mRNA messenger ribonucleic acid
Shh Sonic Hedgehog
TFF Trefoil factor family peptide
TGF Transforming growth factor
TNF Tumor necrosis factor
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INTRODUCTION
The mammalian gastrointestinal tract and liver are self-renewing organs that are able to
sustain themselves due to stem cells present in their tissues. These primitive cells retain
the ability to replicate in an unlimited fashion in order to produce a number of progenitors.
The daughter cells become committed to particular cell lineages, differentiating into
distinct cell types characterictic of the tissue in question. The architecture of the normally
functioning organ is maintained in a highly sophisticated manner that is governed by
multiple molecular pathways, such as TGF-? signaling. TGF-? is considered a key
modulator of the proliferation, cell lineage determination, migration, differentiation, and
eventually, apoptosis. TGF-? is a ligand that exerts its effects on the nucleus via Smad
proteins, which form a complex with specific transcription factors prior to binding to
DNA. One of the suggested transcription factors is GATA-4.
GATA-4 belongs to a zinc finger-containing family of proteins important in the regulation
of transcription in multiple mammalian organs. In tissues derived from endoderm, GATA-
4 and GATA-6 are crucial during organogenesis, as defects in their expressions lead to
premature lethality due to impaired heart formation. GATA-4 is important in
gastrointestinal differentiation as well as hepatogenesis. Moreover, it is thought to be
among the first transcription factors to bind to chromatine to potentiate transcription and
cell determination at the very beginning of life. GATA-5, by contrast, is believed play a
somewhat marginal role in the regulation of cells of the digestive system. GATA-4 and
GATA-5 are considered the ones with tumor suppressive functions, which are inactivated
by methylation. GATA-6 is more related to tumor promotion.
Gastrointestinal inflammation disrupts the epithelial barrier and may induce ulcerations on
the mucosal surface. The gastrointestinal mucosa, as well as the liver parenchyma, has a
remarkable capability for regeneration due to the large population of multipotent stem
cells. In tissue damage, the stem cells are activated to initiate replacement of the injured
epithelium. The reverse side of the coin is that under the stimuli of tumor-promoting
signals, the active stem cell population may become resistant to growth inhibition.
Uncontrolled cell proliferation eventually leads to cancer.
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In this study, we examined the GATA-related molecular pathways involved in normal
tissue organization and renewal and in inflammation-related epithelial repair in the
gastrointestinal tract and liver. We aimed at shedding further light on the expression of
endodermal GATA factors in the tumorigenesis of digestive organs. The overall purpose
of this study was to elucidate the relation of GATA factors to gastrointestinal and hepatic
disease pathology and to evaluate their possible clinical significance in tumor biology.
REVIEW OF THE LITERATURE
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REVIEW OF THE LITERATURE
1 Gastrointestinal morphogenesis
1.1 Fetal and postnatal development
The mammalian gastrointestinal tract develops from a primitive endodermal tube that
gives rise to the pharynx, esophagus, stomach, small intestine, and colon. The gut
endoderm is an important collaborator in the formation of a number of other organs such
as the heart, as well as the gut-derived organs; thyroid, lungs, pancreas, and liver. These
gut derivatives are formed at the dorsal-ventral axis by epithelial-mesenchymal
interactions (Wells and Melton 1999).
The gastrointestinal mucosa comprises a lining epithelium and an underlying mesenchyme
containing, for example, connective tissue, inflammatory cells, and pericryptal
subepithelial myofibroblasts (Figure 1) (Leedham et al. 2005). The morphogenesis of the
gastrointestinal epithelium can be divided into three phases: 1) proliferation and 2) lineage
determination of the gastrointestinal stem cells and 3) the final cellular differentiation.
Figure 1. The establishment of intestinal epithelium. Progeny of the multipotent stem cells give
rise to various gastrointestinal cell types depending on the part of the gut tube along the proximal-
distal axis. In mature intestinal mucosa, the stem cells are located near the base of intestinal crypts,
from where differentiating cells migrate to their specific sites on the crypt-villus axis.
The mucosal architecture of the gastrointestinal tract is completed during the early fetal
period in humans (Montgomery et al. 1999). In mice, formation of the final epithelial
structure of the gut begins right before birth, and the intestinal maturation is completed at
approximately three weeks postnatally during the suckling-weaning transition (Figure 2)
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(Traber and Silberg 1996). However, the alimentary tract undergoes vigorous renewal
throughout the lifetime due to stem cells providing the epithelium with new cells. The
epithelial regeneration is relatively rapid; for example, in the small intestine the lifespan of
a single enterocyte of an intestinal villus is approximately three days, whereas gastric
parietal cells can live up to two months before apoptosis and exfoliation to the lumen
(Karam 1999).
Figure 2.  Intestinal maturation – comparison between humans and mice.
1.2 Functional adaptation of the small intestine
In the small intestine, the absorptive enterocytes, comprising over 95% of the cells in the
villus epithelium, express many specialized proteins required for intestinal function. This
protein expression varies largely according to their age and location along the crypt-villus
and proximal-distal axes. In humans, intestinal enzyme activity is established already
during the fetal period. During the neonatal period the intestinal epithelium receives oral
nutrition. The epithelium adapts to ingested maternal milk rich in fat and maternal
immunoglobulins. During weaning the milk-based diet is replaced by carbohydrates. The
enzymes digesting the nutrients adapt to the dietary changes (Brittan and Wright 2002,
Caicedo et al. 2005). In addition, various hormones, particularly glucocorticoids, influence
intestinal cell maturation and enzymatic expression (Lebenthal and Lebenthal 1999). In
mammalians, the expression levels of many enzymes vary between different periods of
life; for example, lactase is known to diminish after weaning in mice and humans
(Troelsen 2005). In some individuals, lactase expression persists throughout life due to a
single-nucleotide polymorphism in the lactase promoter region (Enattah et al. 2002).
In addition to functional and morphological adaptation, the intestinal mucosa goes through
immunologic changes. The mammalian gastrointestinal tract is characterized by numerous
inflammatory cells located between intestinal enterocytes (M-cells and intraepithelial
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lymphocytes) and in the lamina propria (lymphocytes, plasma cells, eosinophils, Peyer’s
patches) (Mowat 2003). After birth, immune function relies on passive immunity
conferred by maternal immunoglobulins. Construction of the child’s own active immunity
is promoted by both the commensal microflora and introduced pathogens colonizing the
alimentary tract (Caicedo et al. 2005). Foreign antigens activate intestinal immune
responses via Toll-like receptor signaling expressed by macrophages, mesenchymal cells,
and epithelial cells. Information about a particular pathogen is further mediated to
dendritic cells, which induce other inflammatory cells to produce immunoglobulins and
cytokines. The epithelium is thus able to withstand the injury through a complex interplay
of a variety of  immune response cascades (Mowat 2003).
1.3 Liver anatomy and physiology
The liver is the largest internal organ of the human body (weighing 1400 g in adults) and a
major governer of many metabolic functions (Table 1). The liver is formed from an
endodermal bud of the foregut during the first months after gestation. The mesoderm
surrounding the bud strongly supports the growth and differentiation of the hepatic
endoderm (Wells and Melton 1999). A key function of the embryonic liver is the
production of blood cells from five weeks’ gestation (Migliaccio et al. 1986).
Hematopoietic cells appear in small clusters among the hepatic parenchymal cells. As the
liver develops, its cells gradually acquire the capacity to perform specialized functions
characteristic of a mature liver, such as the storage of glycogen and the production of
numerous enzymes and bile (Table 1). Liver hematopoiesis only occurs until the early
postnatal period in humans. In mice, liver hematopoiesis is even more transient, being
active between gestational days 11 and 16 (murine gestation, 21 days) (Yu et al. 1993).
Table 1. Major functions of hepatocytes.
Task Function Product
Protein metabolism Synthesis and secretion Albumin
Prothrombin
Fibrinogen
Aminoacid degradation
Urea cycle
Carbohydrate metabolism Glucose restoration and recruitment
Steroid and lipid metabolism Synthesis and degradation Cholesterol
Fatty acids
Triglycerides
Bile Formation, secretion, and recycling
Drug metabolism Detoxification
Induction of fetal hematopoiesis Synthesis and decretion Erythropoietin
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Figure 3. Structure of the liver lobule.
The liver consists of small units called liver
lobules. The major hepatic cell type, hepatocytes,
are organized into plates surrounding the dilated
venous capillaries, sinusoids, which are lined by
three different cell types: sinusoidal endothelial
cells, Kupffer cells, and hepatic stellate cells. In
addition, intrahepatic lymphocytes, including
natural killer (NK) cells, are often present in the
sinusoidal lumen. The hepatic plates and sinusoids
radiate from the central vein, forming a functional
unit called liver lobule. This polygonal structure is
immediately attached to neighboring lobules
between which hepatic arteries, bile ducts, and
portal veins (hepatic triad) are located (Saxena et
al. 1999).
The liver has the ability to regenerate to its original size even after up to two-thirds of the
organ have been removed (Sell and Leffert 2008). Hepatocytes, which comprise the
majority of the hepatic tissue, consist of a rather heterogeneous population of cells. They
have a relatively long lifespan and are able to proliferate in response to tissue resection or
cell death. Moreover, quiescent stem cells, ovalocytes, can be found in the intrahepatic
bile ductules, the canals of Hering, between the bile canaliculi and the interlobular bile
ducts (Figure 3). In contrast to hepatocytes, ovalocytes are activated in severe hepatic
injury (Forbes et al. 2002).
2 Regulation of differentiation in the gastrointestinal tract
2.1 Gene regulation
The regulation of cellular differentiation and function involves transcription factors, which
control the initiation of gene transcription. Transcription factors are proteins that recognize
a specific deoxyribonucleic acid (DNA) sequence in the promoter region of the target
gene. Together with their cofactors and cooperative factors, transcription factors either
trigger or hinder the synthesis of messenger ribonucleic acid (mRNA), which is further
translated into proteins. Transcription factor activity may be restrained by silencing the
DNA encoding the factor itself, or inhibiting the nuclear translocation of the transcription
factor or the binding to DNA. The structure of the DNA may also be distorted due to
epigenetic changes, such as methylation of the DNA or posttranslational modifications
(e.g. phosphorylation, acetylation, and methylation) of the chromatin-packaging proteins,
histones (Berger 2007). Given that the regulation of a single gene usually involves a wide
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variety of factors, a particular transcription factor is seldom indispensable. However,
crosstalk between the regulatory pathways may be altered, which, in the long term, affects
cellular differentiation and function. Transcription factors considered important in the
gastrointestinal tract and liver are discussed below.
2.1.1 GATA transcription factors
GATA proteins are characterized by their zinc finger binding domains with which they
bind to specific target genes in DNA, enabling transcriptional activation. They regulate
cellular development and differentiation in many human organs. GATA-1, GATA-2, and
GATA-3 are known to function in the hematopoietic system (Orkin 1992). GATA-4,
GATA-5, and GATA-6 are found in the heart and in other organs of endodermal origin
(Table 2) (Molkentin 2000).
Table 2. GATA factors in mice and humans.
Expression Mouse -/- phenotype Human mutation Reference
GATA-1 Hematopoietic lineage
Testis
Lethal (E11.5),
defects in
hematopoiesis
Anemia,
thrombocytopenia
(Ito et al. 1993)
(Fujiwara et al. 1996)
(Nichols et al. 2000)
GATA-2 Hematopoietic lineage
Central nervous
system
Lethal (E11.5),
defects in
hematopoiesis
Acute phase of
chronic myeloid
leukemia
(Tsai et al. 1994)
(Nardelli et al. 1999)
(Zhang et al. 2008)
GATA-3 T-lymphocytes
Central nervous
system
Lethal (E11.5), defects
in hematopoiesis and
central nervous system
HDR syndrome (Pandolfi et al. 1995)
(Van Esch et al. 2000)
(Ho and Pai 2007)
GATA-4 Heart
Digestive organs
Gonads
Lethal (E10.5), defects
in ventral
morphogenesis and
heart formation
Congenital heart
defects
(Kuo et al. 1997)
(Molkentin et al. 1997)
(Garg et al. 2003)
GATA-5 Heart
Digestive organs
Genitourinary tract
Nonlethal defects in
female genitourinary
tract
Not detected
(Laverriere et al. 1994)
(Morrisey et al. 1997)
(Molkentin 2000)
GATA-6 Heart
Digestive organs
Lung
Lethal (E7.5), failure in
gastrulation Not detected
(Morrisey et al. 1996)
(Suzuki et al. 1996)
(Morrisey et al. 1998)
Abbreviations: E, embryonic day; HDR, hypoparathyroidism-deafness-renal dysplasia
During murine embryogenesis, GATA-4 and GATA-6 are present from the early
formation of the primitive gut tube until the normal postnatal renewable epithelium is
formed (Molkentin 2000). Knockout experiments have proven that they both play a crucial
role in the formation of several endodermal organs. Lack of either GATA-4 or GATA-6
leads to failure in ventral morphogenesis, through which the digestive system is generated,
and these mice die of cardiac defects by embryonal age 10.5 (Kuo et al. 1997, Molkentin
et al. 1997, Morrisey et al. 1998). GATA-5 is the only endodermal GATA factor
dispensable in embryonic development (Molkentin 2000). However, endodermal GATA-4
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expression can counteract GATA-4 deficiency in the mesoderm and enable the
morphogenesis of endodermal organs (Narita et al. 1997b).
In the gastrointestinal tract, GATA-6 is localized to intestinal crypts containing
proliferative cells (Gao et al. 1998). In vitro, GATA-6 expression is downregulated during
intestinal cell differentiation and is thereafter confined to undifferentiated cells (Gao et al.
1998). In the developing murine intestinal mucosa, GATA-4 is among the first
transcription factors to bind to chromatin, enabling further protein binding by other factors
(Bossard and Zaret 1998). Later on, GATA-4 is suggested to be associated with cell
differentiation. In mice chimeric for GATA-4, the gastric epithelial lineages perform poor
differentiation (Jacobsen et al. 2005). Recently, GATA-4 action was blocked in the
murine small intestine by targeted deletion using villin promoter, which led to a change
from a small intestinal to a of large intestinal phenotype (Bosse et al. 2006). GATA-4 was
consequently suggested to control tissue- and site-specific differentiation in the
gastrointestinal tract. Both GATA-4 and GATA-6 regulate a variety of genes characteristic
of gastric and intestinal mucosa, whereas GATA-5 presents a less versatile role in the
control of gastrointestinal functions (Table 3). The regulation of transcription by GATA
proteins appears, however, to involve a complex network of cofactors, cooperators,
promoters, and repressors.
Table 3. GATA factors in gastrointestinal and hepatic gene regulation in mammalian cells in
vitro.
Target gene Regulator Cell type Tissue Reference
H+/K+-ATPase GATA-4/6 Parietal cell Stomach (Nishi et al. 1997)
Trefoil factor 1/2 GATA-6 Surface/neck cells
Goblet cell
Stomach
Small intestine
(Al-Azzeh et al. 2000)
Mucins GATA-4/5 Surface cell
Goblet cell
Stomach
Intestine
(Ren et al. 2004, Van
Der Sluis et al. 2004)
Intestinal alkaline
phosphatase
GATA-4 Enterocyte Small intestine (Belaguli et al. 2007)
Lactase phlorizin
hydrolase
GATA-4/5/6 Enterocyte Small intestine (Fang et al. 2001)
Sucrase-isomaltase GATA-4 Enterocyte Small intestine (Boudreau et al. 2002)
Sodium-hydrogen
exchanger
GATA-5 Enterocyte Small intestine (Kiela et al. 2003)
GIP GATA-4 K-cell* Small intestine (Jepeal et al. 2008)
Intestinal fatty acid
binding protein
GATA-4 Enterocyte
Hepatocyte
Small intestine
Liver
(Belaguli et al. 2007)
Liver fatty acid binding
protein
GATA-4 Enterocyte
Hepatocyte
Small intestine
Liver
(Divine et al. 2003)
Apoliprotein A1 GATA-4/6 Enterocyte
Hepatocyte
Small intestine
Liver
(Ivanov et al. 2003)
Erythropoietin GATA-4 Hepatocyte Liver (Dame et al. 2004)
Abbreviations: GIP, glucose-dependent insulinotropic polypeptide
* K cell, a specific intestinal neuroendocrine cell type
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GATA factors in tumorigenesis
GATA-4 and GATA-6 are associated with tumorigenesis in multiple organs, e.g. adrenals
(Kiiveri et al. 1999), ovaries (Laitinen et al. 2000), and yolk sac (Siltanen et al. 1999). In
the gastrointestinal tract, GATA-4 overexpression is demonstrated in adenocarcinomas of
the esophagus (Lin et al. 2000). The role of GATA proteins in tumorigenesis remains
under debate. GATA-6 has been shown to arrest the cell cycle by inducing cyclin-
dependent kinase inhibitor (CKI) p21 (Perlman et al. 1998, Nagata et al. 2000, Setogawa
et al. 2006) and to inhibit apoptosis of malignant cells (Shureiqi et al. 2002). GATA-4 is
also involved in the inhibition of apoptosis through upregulation of antiapoptotic factor
Bcl-2 (Kobayashi et al. 2006). However, GATA-4 and GATA-5 are proposed to act as
tumor suppressors, and inactivation of GATA-4 and GATA-5 genes by methylation
induces tumorigenesis (Akiyama et al. 2003).
2.1.2 Friends of GATA factors
Friends of GATA (FOGs) factors are zinc finger-containing proteins. They act as GATA
cofactors and are able to modulate the activity of GATA proteins. To date, two FOG
proteins have been identified in mammalians. Both factors interact with each of the six
GATA transcription factors (Cantor and Orkin 2005). The coexpression of FOG-1 with
GATA-1 was first detected during murine embryonic hematopoiesis. Mice devoid of
FOG-1 die of severe anemia during midgestation (Tsang et al. 1998). In addition to such
hematopoiesis-related tissues as the liver, FOG-1 is expressed in the embryonic murine
gastric epithelium (Jacobsen et al. 2005) and in the stomach and small intestine of human
adults (Freson et al. 2003).
FOG-2 exerts most of its functions by interacting with GATA-4 via its zinc fingers. No
direct binding activity to DNA has yet been detected for FOG-2 (Cantor and Orkin 2005).
In the heart, a mutation in the GATA-4 amino-terminal finger causes a FOG-2 null-like
phenotype, disturbing cardiac development in mice (Crispino et al. 2001). FOG-2 is
detected in the gut of murine embryos (Tevosian et al. 1999), whereas in adults it is
expressed at low levels only in the liver (Svensson et al. 1999). In addition to the
mediation of GATA function, FOG proteins may antagonize GATA factors depending on
the target gene and the cell type (Cantor and Orkin 2005).
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2.1.3 Hepatocyte nuclear factors
Hepatocyte nuclear factors (HNFs) were first identified in the liver. In the gastrointestinal
tract, HNF-1 and HNF-4 families have been implicated in the regulation of a number of
intestine-specific genes, e.g. fatty acid binding proteins (FABPs), and sucrase-isomaltase
(SI) (Rottman and Gordon 1993, Boudreau et al. 2001). HNF-1? and HNF-1? share the
same DNA binding site and are able to homodimerize or heterodimerize with each other
(Mendel et al. 1991). Additionally, HNF-4 is involved in the regulation of a gene
encoding HNF-1? (Kuo et al. 1992). HNFs work in concert with other transcription
factors, such as GATA factors (Boudreau et al. 2002, Divine et al. 2003). Mice
homozygous for HNF-1? -/- die during weaning due to a severe wasting with liver
enlargement (Pontoglio et al. 1996). Decreased expression of HNF-1? as a consequence of
a mutated HNF-4 binding site is implicated in maturity onset diabetes (Gragnoli et al.
1997). HNF-1? interacts directly with the HNF-4 domain and is, curiously, able to
negatively regulate its own expression as well as that of other HNF-4-related genes
(Ktistaki and Talianidis 1997). HNF-4 has also been reported to have multiple isoforms
that play distinct roles in differentiating intestinal epithelial cells (Suaud et al. 1997,
Lussier et al. 2008).
HNF-1? and HNF-1? mRNA is detected in murine intestinal crypts (Serfas and Tyner
1993), whereas villus enterocytes express HNF-1? protein (Boudreau et al. 2002). HNF-1
family members are found throughout development in the rodent liver (De Simone et al.
1991). Contrarily, in humans, HNF-1? is confined to fetal hepatocytes (Limaye et al.
2008). HNF-4 is robust in the adult liver (Sladek et al. 1990, Limaye et al. 2008) and is a
pivotal regulator of hepatic gene expression (Sladek 1994). Lack of HNF-4 during
embryogenesis disrupts the expression of multiple genes involved in lipid metabolism and
bile production (Watt et al. 2003). In the gastrointestinal tract, HNF-4 isoforms are
expressed in the intestinal cells (Nakhei et al. 1998).
2.1.4 Hedgehog signaling
Hedgehog (Hh) signaling is one of the key molecular pathways in the embryonic
development of the gastrointestinal system. The Hedgehog family of proteins consists of
three members: Desert, Sonic, and Indian Hedgehog (Lees et al. 2005). Sonic Hedgehog
(Shh) and Indian Hedgehog (Ihh) are highly expressed in epithelial cells of the murine
embryonic gut (Ramalho-Santos et al. 2000, Madison et al. 2005), whereas the other
components of the Hh signaling pathway, such as transmembrane proteins patched (Ptc)
and the transcription factor Gli, are found almost exclusively in the mesenchyme
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(Ramalho-Santos et al. 2000, Madison et al. 2005). This allows a crosstalk between the
endoderm and mesoderm critical for normal gastrointestinal patterning. Both Shh and Ihh
knockout mice die perinatally of various gastrointestinal pathologies, such as gastric
hyperplasia, malrotation, and dysgenesis of the subepithelial neurons (Ramalho-Santos et
al. 2000). In the human adult gastrointestinal tract, Shh persists along the whole gut tube,
predominantly at the base of the epithelium (Van Den Brink et al. 2002, Nielsen et al.
2004). Expression of Ihh in the human digestive system has earlier been detected in the
liver and stomach. In the colon, Ihh has been observed in surface enterocytes, suggesting a
role in colonocyte differentiation (Marigo et al. 1995, Van Den Brink et al. 2002, Fukaya
et al. 2006).
Upregulation of Shh has been detected in areas of chronic inflammation, such as Barrett’s
esophagus, Crohn’s disease, and ulcerative colitis (Nielsen et al. 2004). Shh is therefore
proposed to enhance tissue repair in acute epithelial injury. Nevertheless, the exact roles of
Shh and Ihh in gastrointestinal cancers remain somewhat controversial; Hh signaling is
implicated in the induction and maintenance of malignant tumor growth in many organs,
including the gastrointestinal tract (Berman et al. 2003, Pasca Di Magliano and Hebrok
2003, Katoh and Katoh 2005), but it may also restrict tumor progression by antagonizing
the cancer-associated Wnt pathway (Van Den Brink and Hardwick 2006).
2.1.5 Wnt and Notch signaling pathways
Canonical Wnt signaling is important in several processes involving gastrointestinal
development and renewal. It maintains gastrointestinal stem cells in the proliferative state
via cell cycle control, and directs epithelial cell migration, localization, and terminal
differentiation in the intestine (Scoville et al. 2008). Alterations in the Wnt signaling
pathway contribute to intestinal tumorigenesis (Radtke and Clevers 2005). When Wnt
signaling is blocked, all secretory cells are lost (Pinto et al. 2003). The signaling cascade
is initiated by secreted Wnt proteins [20 found in mammals (Nakamura et al. 2007b)],
which bind to Frizzled cell surface receptors. Cytoplasmic protein ?-catenin is
consequently stabilized, allowing its entrance into the cell nucleus, where it induces gene
transcription together with its cofactor, T-cell factor (Tcf) (Scoville et al. 2008).
Notch signaling is considered to control cell fate decisions and subsequent differentiation
between adjacent precursor cells in intestinal crypts. The binding of a Notch ligand to the
transmembrane receptor of the neighboring cell leads to proteolytic cleavage of the Notch
receptor. The intracellular domain is translocated into the nucleus, where it activates the
transcription of Notch target genes, such as the hairy/enhancer of split (Hes)
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transcriptional repressors (Sancho et al. 2004). Notch signaling components are expressed
in both fetal and adult intestines of the mouse, possibly directing enterocyte differentiation
(Schroder and Gossler 2002). Lack of the Notch target gene Hes-1 increases the number of
intestinal secretory and neuroendocrine cells at the expense of absorptive enterocytes
(Jensen et al. 2000). Math-1, which is repressed by Hes-1, plays the opposite role in cell
fate choice, as lack of it leads to decreased population of secretory cells (Yang et al.
2001).
Similarly to Wnt, Notch signaling appears to be required for the maintenance of
proliferation. Thus, both Wnt and Notch are entailed to the multipotent progenitors of the
gastrointestinal epithelium. Once the progenitor cell escapes the transit-amplifying
compartment of the epithelium (i.e. site of proliferation) (Figure 1), it is directed by either
of these signaling pathways towards the secretory cell (Wnt) or the absorptive cell (Notch)
lineage (Nakamura et al. 2007b). The crosstalk between these two pathways is inevitably
extremely delicate and is still largely unelucidated. At any rate, both pathways are
essential for the lineage commitment of the gastrointestinal precursor cells.
2.1.6 Other transcription factors
Numerous other transcription factors are involved in gastrointestinal development and
function. These factors include the bone morphogenetic proteins (BMPs, belonging to the
Transforming growth factor (TGF)-? superfamily discussed later) (Sancho et al. 2004), the
Eph/ephrin pathway (Crosnier et al. 2006), the forkhead family of transcription factors,
and the caudal homologs (Cdx) (Brittan and Wright 2002). Many of these factors probably
function in cooperation with other molecular pathways to activate transcription in the
digestive system. In addition to this, a large panel of factors regulate the epithelial cell
apoptosis in the intestine, such as the Bcl-2 protein family consisting of both pro- and
antiapoptotic factors (Youle and Strasser 2008). The regulatory network governing
mucosal morphogenesis and maintenance requires an extremely complex interplay of a
number of different factors. The challenge is to understand the whole set of signals
working as a system in the epithelial patterning and renewal.
2.2 Cell cycle regulation
The coordination of proliferation and differentiation in the constantly regenerating tissue
is crucial for epithelial homeostasis. As the stem cell progenitors reach the crypt-villus
junction, the cell cycle is normally halted enabling differentiation. Impaired cell transition
from the proliferative state to the subtle program of epithelial cell specification may lead
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to mucosal changes such as tumor growth, digestive malfunction, or mucosal atrophy.
Many of the above-mentioned factors affect the proteins involved in the cell cycle.
         Figure 4. Cell cycle regulation.
One of the major regulators of the cell cycle is the E2F family of transcription factors,
which guide the gastrointestinal stem cells from G1 into S phase (Brittan and Wright
2002). Other important cell cycle regulatory proteins are the pocket proteins (e.g. pRb,
p107, and p130), which, when unphosphorylated, arrest the cell cycle by binding to E2F
(Deschenes et al. 2004). Cyclins and cyclin-dependent kinases (Cdks) inhibit the pocket
protein binding to E2F, thus allowing the transcription of the S phase genes (Figure 4).
Mammalian cells express several different Cdk inhibitors, which contribute to the cell
cycle arrest. The CKIs (e.g. p21 and p27) impede the cyclin-Cdk complex-mediated
phosphorylation of pocket proteins. CKIs are thus responsible for the inhibition of E2F
(Massague 2004). Through this action, the CKIs are able to initiate differentiation.
2.3 Gastrointestinal peptide growth factors
A large number of regulatory peptides is expressed in the gastrointestinal mucosa. They
are shown to modulate a variety of gastrointestinal cell populations. Peptide growth
factors tend to act locally on adjacent cells (paracrine action), but also in an autocrine
fashion. The peptides bind to specific cell surface receptors on the target cells and regulate
stem cell differentiation and migration as well as extracellular matrix deposition and
degradation (Dignass 2001).
2.3.1 Transforming growth factor beta
The TGF-? superfamily of growth factors comprises TGF-? family members, BMPs, and
activins. Three isoforms of TGF-? have been identified in the human and mouse
gastrointestinal tract. TGF-?1 is the most prominent factor, which is expressed especially
in the differentiated cells of the gut, where also TGF-?2 and TGF-?3 are present, although
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to a lesser extent. In addition to this, TGF-?2 is found in the submucosal regions of the
epithelium (Tanigawa et al. 2005).
TGF-? binds to a serine/threonine kinase cell membrane receptor that triggers the
intracellular TGF-? signaling pathway (Figure 5). The cytoplasmic TGF-? mediators, the
Smad proteins, translocate into the cell nucleus and activate gene transcription through
interaction with other transcription factors, coactivators, and corepressors (Tanigawa et al.
2005). TGF-? signaling interacts with other signaling cascades, such as the Wnt pathway
(Nishita et al. 2000). In addition, signaling via Smad proteins is utilized also by BMP
signaling (Sancho et al. 2004). One of the suggested trancription factors acting in concert
with Smad proteins is GATA-4 (Brown et al. 2004, Anttonen et al. 2006, Belaguli et al.
2007).
Figure 5. TGF-? signaling pathway.
The TGF-? signaling pathway is activated by the TGF-? ligand binding to type I and type II cell
membrane receptors, which are also utilized by Activin. The receptor phosphorylates cytoplasmic
protein Smad2 or Smad3, which together with Smad4 translocates into the cell nucleus and
activates gene transcription through interaction with other transcription factors, such as GATA-4.
Modified from Tanigawa, et al. (2005).
TGF-? has a large number of biological effects on various gastrointestinal cell types. It is
suggested to function as a regulator of epithelial morphogenesis. TGF-? arrests the cell
cycle in the G1 phase in vitro, allowing epithelial cell migration and differentiation. It is
also considered to coordinate cell turnover (Tanigawa et al. 2005). TGF-? is thought to act
as a protective growth factor in the intestinal mucosa, promoting epithelial restitution and
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repair (Beck and Podolsky 1999) as well as suppressing proinflammatory cytokines, such
as interleukin(IL)-6 (Walia et al. 2003). It is responsible for the synthesis and secretion of
immunoglobulin A (IgA) in B-cells of the lamina propria (Park et al. 2001). TGF-?
increases the formation of extracellular matrix proteins and proteinase inhibitors
(Tabibzadeh 2002). Moreover, TGF-? is suggested to accelerate the proliferation of
fibroblasts, thus playing a role in wound healing and tissue fibrosis (Tanigawa et al.
2005).
TGF-? is speculated to selectively eliminate preneoplastic cells via CKI-induced cell cycle
escape and apoptosis in order to suppress tumor growth. Loss of TGF-? may therefore
predispose the tissue to cancer (Gold 1999). Mice knockout for TGF?1 present increased
hepatocyte proliferation and decreased apoptosis in the liver (Tang et al. 1998). A
majority of gastrointestinal tumors demonstrate impaired TGF-? signaling (Mishra et al.
2005). Despite its potency in inhibiting abnormal growth, TGF-? can also act as a
promoter of tumorigenesis. Some tumors also secrete TGF-? into the circulation
(Langenskiold et al. 2008).  The tumor cells themselves may lose their responsiveness to
TGF-?-mediated growth inhibition and therefore exhibit enhanced tumor cell migration
and invasiveness under the influence of TGF-? (Massague et al. 2000).
2.3.2 Other gastrointestinal peptides
The complex network of regulatory peptides includes numerous other growth hormones.
TGF-? is considered the most significant ligand of the epidermal growth factor (EGF)
family in the gastrointestinal mucosa. TGF-? stimulates proliferation in intestinal
epithelial cells. It may contribute to an increased risk of malignancy in chronic
gastrointestinal inflammation (Babyatsky et al. 1996, Dignass and Sturm 2001) and is
strongly expressed in liver carcinoma (Breuhahn et al. 2006). Another group of growth
factors contributing to invasive growth of tumor cells is the family of insulin-like growth
factors (IGFs) (Breuhahn et al. 2006). They promote wound healing and are involved in
inflammation-related mucosal fibrosis. IGFs exert their effects on gastrointestinal
epithelial and nonepithelial cells through cell surface receptors in an autocrine mechanism
(Dignass and Sturm 2001).
Fibroblast growth factor (FGF) family peptides and receptors control the proliferation and
differentiation of epithelial, endothelial, and mesenchymal cells in the intestine as well as
in the liver (Dignass and Sturm 2001, Breuhahn et al. 2006). In cell line studies, FGF-1
and FGF-2 induce the restitution of intestinal epithelium through a TGF-?-dependent
pathway. Contrarily, the trefoil factor family (TFF) action on gastrointestinal epithelium is
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independent of TGF-?. The TFF family includes three members: TFF1 and TFF2 are
expressed in the mucin-producing cells of the stomach and small intestinal Brunner
glands, whereas TFF3 is absent from the stomach, but is expressed in the Brunner glands
as well as goblet cells along the whole intestine. Of note, knockout mice for TFF1 develop
gastric tumors. TFFs are thus suggested to play a role as a tumor suppressor as well as an
inducer of cell migration (Dignass and Sturm 2001).
Hepatocyte growth factor (HGF) is the most potent growth factor in the liver. It has a
variety of biological activities in normal hepatocytes and gastrointestinal epithelial cells.
The only known receptor for HGF is Met, which is reported in most hepacellular
carcinomas (HCCs). Interestingly, many childhood HCCs tend to present mutations in the
Met tyrosine kinase domain, which is not detected in adult HCCs. The HGF/Met pathway
is also known to interact with the TGF-?/Smad signaling pathway (Breuhahn et al. 2006).
2.4 Epithelial-mesenchymal interactions
Gastrointestinal morphogenesis and homeostasis are dependent on crosstalk between
epithelial cells and their adjacent mesenchymal cells (Montgomery et al. 1999). Immature
epithelial cells require the presence of the mesenchyme for site-specific cell
differentiation. Reciprocally, a proper composition of the lamina propria is dependent on
endodermal signals. Epithelial-mesenchymal communication involves the previously
discussed paracrine growth factors, the cell-cell contacts, and the basement membrane
molecules (Crosnier et al. 2006).
Figure 6. Components of epithelial-
mesenchymal crosstalk in the intestinal
mucosa.
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The basement membrane lies between the epithelial cells and mesenchymal
myofibroblasts, following the shape of the epithelial lining in the crypts and the villi
(Figure 6). It is composed of a variety of molecules, such as laminins and collagens,
depending on the developmental stage and the crypt-villus position. The extracellular
matrix exerts its signals to the endoderm via a set of integrin receptors, further activating
the intracellular signaling pathways and transcription in epithelial cells. In addition to the
molecular induction, gut morphogenesis and differentiation require actual contact
between epithelial and mesenchymal cells, allowing a supplementary production of
basement membrane molecules (Kedinger et al. 1998).
3 Gastrointestinal and hepatic inflammation
The gastrointestinal epithelium represents a crucial barrier to a broad spectrum of noxious
substances in the intestinal lumen. Inflammation may lead to impaired barrier function.
The injured epithelium is rapidly re-established by increased cell proliferation, migration,
and differentiation. Healing is regulated by a complex network of cytokines and peptide
molecules and a variety of transcription factors. Constant epithelial damage is associated
with structural and functional changes in the gastrointestinal mucosa and may lead to
cancer.
3.1 Pathophysiology of inflammation
3.1.1 Gastritis and esophagitis
Helicobacter pylori infection is one of the most common bacterial infections worldwide.
The bacterial transmission possibly occurs during early childhood from the infant’s
mother. H. pylori is the predominant cause of peptic ulcers and chronic gastritis in
humans. Curiously, H. pylori seems to protect the individual from gastroesophageal reflux
disease (Makola et al. 2007). The bacteria disrupt the gastric epithelium and initiate
immune responses, further damaging the mucosa. Increased levels of gastrin and
hydrochloric acid are characteristics of antral gastritis, while more diffuse gastritis
presents as low gastric acid secretion (Suerbaum and Michetti 2002). In diffuse gastritis,
the acid-secreting gastric glands die out leading to mucosal atrophy, whereas the gastrin-
producing neuroendocrine cells perform grow excessively. Chronic immune activation
may lead to hyperplasia of the gastric lymphoid follicles. The most significant change is
the replacement of the gastric epithelium by intestinal metaplasia (Makola et al. 2007).
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The major risk factor of esophagitis is gastroesophageal reflux disease. This leads to
epithelial injury, inflammation, and abnormal growth. Similarly, gastritis-induced
metaplasia of the stomach, chronic reflux-related inflammation, may lead to the
substitution of the squamous epithelium by columnar epithelium in the esophagus, where
constant reflow of gastric acids occurs (Orlando 2008). To summarize, chronic
inflammation in the esophagus and stomach predisposes the epithelium to metaplasia and
further to cancer.
3.1.2 Celiac disease
Celiac disease is a multifactorial inflammatory disorder affecting the small intestinal
mucosa. It is characterized by mucosal atrophy due to exposure to a gluten-containing
diet. In the early stages of the disease the gluten triggers lymphocytes to infiltrate the
epithelium and underlying lamina propria and to secrete harmful cytokines. Gradually,
immune responses lead to the flattening of villi and compensatory crypt hyperplasia (Maki
and Collin 1997). The mucosal changes resemble those found in microbial infections or
food allergy (Savidge et al. 1996). While the rate of the crypt cell mitosis is increased, the
Fas ligand-mediated apoptosis is also accelerated (Ciccocioppo et al. 2001). Celiac disease
enteropathy leads to decreased expression of brush border enzymes and malabsorption,
and the disease can be arrested only by adhering to a gluten-free diet (Maki and Collin
1997).
3.1.3 Inflammatory bowel disease
Crohn’s disease and ulcerative colitis are the two major forms of inflammatory bowel
disease (IBD). The pathogenesis is thought to be associated with a defective mechanism in
mucosal defense and repair due to environmental factors and genetic susceptibility
(Sanders 2005, Baumgart and Sandborn 2007). The pattern of inflammation in Crohn’s
disease is transmural, with granulomas affecting both the small and large intestine. In
ulcerative colitis, the inflammation is usually more diffuse, but restricted to the mucosal
layers of the colon. Histological distinction between Crohn’s disease and ulcerative colitis
as well as other intestinal inflammations is often difficult, and serological tests are
somewhat unreliable (Baumgart and Sandborn 2007).
In IBD, the intestinal immune system is impaired. Luminal bacteria enter the intestinal
mucosa via a leaky epithelial barrier. The bacterial antigens trigger several inflammatory
pathways. The antigen-recognizing dendritic cells, as well as the epithelial cells, present
the antigens to T-cells, which secrete proinflammatory peptides and stimulate other
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inflammatory cells. Characteristic of IBD mucosa is an increased number of antigen-
responding epithelial M-cells and lymphatic cells in both the epithelium and the swollen
lamina propria. Both crypt cell proliferation and cytokine-induced apoptosis are
enhanced. The exaggerated immune responses and the accelerated cell lifespan lead to a
vicious cycle of further leakage of the epithelium, impaired mucosal architecture, and
ulceration (Baumgart and Carding 2007).
3.1.4 Hepatitis
The etiology of hepatitis is extremely heterogeneous. The major causes of hepatitis are
viral infections, autoimmune reactions, biliary disorders, and drug-induced hepatitis
(Rosenthal 2008). Many extrahepatic inflammations such as IBD associate with
nonspecific reactive hepatitis (Saich and Chapman 2008). In chronic hepatitis, the normal
liver architecture is disrupted. The liver tissue is characterized by the accumulation of
inflammatory infiltrates and monocytes in the portal tracts and the liver parenchyma. The
hepatocytes become swollen and undergo necrosis. The proliferative activity of the
fibroblasts is markedly increased, and collagens, such as type I, accumulate in the liver
tissue. As the walls of the liver sinusoids become fibrotic, hepatic blood flow and nutrient
and metabolite exchange between hepatocytes and plasma are disturbed. Vigorous
hepatocyte regeneration is seen in the branched sinusoidal plates and giant cell
transformations of the hepatocytes. In chronic hepatitis, the tissue damage may become
irreversible and lead to the development of liver cirrhosis, with an increased risk of
hepatocellular carcinoma (HCC) (Guyot et al. 2006).
In response to inflammation-related parenchymal cell loss, the hepatocytes re-enter the
cell cycle from the G0 phase (Forbes et al. 2002). In massive hepatocellular damage, oval-
like stem cells are activated in the canals of Hering (Lowes et al. 2003). The extent of the
oval cell proliferation and differentiation into hepatocytes and biliary epithelial cells
depends on the severity of tissue injury (Lowes et al. 1999). The cytokines secreted by
Kupffer cells and stellate cells act in concert to control the oval cell activation and the
regeneration and remodeling of the liver parenchyma (Lowes et al. 2003).
3.2 Inflammation-related factors
The regulatory peptides are relevant in intestinal repair due their induction of cell
proliferation, migration, and differentiation. TGF-?1/2/3, a protective cytokine, plays an
important role in several protective cascades in the intestine. In the liver, TGF-?, released
by Kupffer cells, induces regeneration of the parenchyma, but also restricts tissue
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overgrowth via the induction of apoptosis (Lowes et al. 2003). The expressions of both
TGF-? ligands and their receptors are induced in the inflamed bowel mucosa
(Beck and Podolsky 1999). In animals with trinitrobenzene sulfonic acid (TNBS)-induced
colitis, TGF-? seems to enhance oral tolerance, reducing the severity of bowel
inflammation (Neurath et al. 1996). TGF-? stimulates the differentiation and migration of
epithelial cells and participates in re-epithelialization, wound closure, and healing.
Disruption of TGF-? and its downstream signaling by Smad proteins is shown to lead to
severe intestinal inflammation as well as tumorigenesis (Yang et al. 1999, Hahm et al.
2001, Sancho et al. 2004).
Activated T-cells and other inflammatory cells secrete proinflammatory cytokines, such as
Interferon ? (IFN- ?) and Tumor necrosis factor ? (TNF-?), which are required in the
generation of a normal intestinal lymphocyte population. In the liver, TNF-? triggers oval
cells to enhance hepatic regeneration (Lowes et al. 2003). In IBD, increased expression of
TNF-? significantly contributes to tissue damage. It suppresses antiapoptotic signals, thus
inducing cell death and promoting epithelial disruption (Koshiji et al. 1998).
Consequently, many therapies of IBD are targeted to inhibit TNF-? action (Baumgart and
Sandborn 2007).
Defects in epithelial cell mucin and Paneth cell defensin production have been reported in
IBD to contribute to disturbed barrier function (Smithson et al. 1997, Buisine et al. 1999,
Shi 2007). The tight junctions between epithelial cells are also shown to be abnormal due
to reduced production of occludin and cell adhesion protein E-cadherin (Gassler et al.
2001, Kucharzik et al. 2001). Another group of factors associated with the epithelial
barrier as well as migration are TFFs, which are downregulated by TNF-? in vitro (Loncar
et al. 2003).
4 Gastrointestinal tumors
In the normal gastrointestinal tract, epithelial regeneration requires a delicate balance
between proliferation and apoptosis. The process is regulated by a complex network of
signal transduction pathways, such as TGF-? signaling (Tanigawa et al. 2005). In chronic
inflammation, the epithelium is constantly disrupted and the cytokine and growth factor
profiles are altered. Many transcription factors involved in the maintenance of homeostasis
may become inactivated by methylation. The altered regulatory cascades (Table 4)
eventually increase the risk of gastrointestinal cancer (Baylin and Herman 2000).
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Table 4. Malignant gastrointestinal and hepatic tumors: Incidence in Finland, diagnostic
markers, and suggested molecular pathways.
Tumor Incidence1
cases/year
Serologic markers1
(sensitivity)
Molecular pathways2
Gastrointestinal tract
Esophageal cancer 250 - EGF, p53
Gastric cancer 1500 - E-Cadherin, TGF-?
Colon cancer 2000 S-CEA (35%) APC, p53, TGF-?
Gastrointestinal carcinoids <30 *S-/U-5-HIAA (low) p53, Bcl-2
Liver
Cholangiocarcinoma 400 S-CA-19-9 (moderate) Wnt
Hepatocellular carcinoma 250 S-AFP (75%) Wnt, TGF-?3
Hepatoblastoma <10 S-AFP (90%) APC (Wnt)
Abbreviations: EGF, Epidermal growth factor; S-AFP, serum alpha-fetoprotein; TGF-?,
transforming growth factor beta; APC, adenomatous polyposis coli; S-CA-19-9, serum
carbohydrate antigen 19-9
* S-5-HIAA, serum 5-hydroxy indoleacetic acid: Serum levels rise, but after hepatic metastases,
urine levels better for follow-up
References: 1 (Salo 2004), 2 (Liu 2005), and 3 (Jakowlew 2006)
4.1 Gastrointestinal neoplasias
4.1.1 Barrett’s esophagus and intestinal metaplasia of the stomach
Barrett’s esophagus, a precursor lesion for esophageal adenocarcinoma, is a metaplastic
columnar epithelium that replaces the squamous epithelium of the normal lower
esophagus as a result of chronic gastroesophageal reflux (Spechler and Goyal 1986).
Intestinal metaplasia of the stomach, in turn, is considered to precede an intestinal type of
gastric cancer. Intestinal metaplasia and mucosal atrophy of the stomach most often
develop after chronic gastric inflammation caused by Helicobacter pylori (Correa and
Houghton 2007). Signaling pathways, such as Hedgehog and TGF-? signaling, are
suggested to be associated with gastric tumorigenesis (Ebert et al. 2000, Katoh and Katoh
2005). There are also changes in gastroprotective TFF expression in intestinal metaplasia
of the stomach, gastric carcinomas, and Barrett’s esophagus (Labouvie et al. 1999, Leung
et al. 2002, Warson et al. 2002, Van De Bovenkamp et al. 2003).
4.1.2 Neuroendocrine tumors
Neuroendocrine tumors, i.e. carcinoid tumors, can be found throughout the gastrointestinal
tract. Carcinoids develop mostly from enterochromaffin-like (ECL) cells. The tumor may
result from mucosal atrophy or neuroendocrine cell neoplasia. In the stomach, the
carcinoids are usually associated with H. pylori-induced atrophic gastritis and
hypergastrinemia. The well-differentiated carcinoids induced by hypergastrinemia found
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in mucosal atrophy or Zollinger-Ellison’s syndrome-related gastrinoma are considered
benign because they seldom disseminate. In contrast, primary carcinoids (neuroendocrine
carcinoma) represent a more malignant growth, with distant metastases (Delle Fave et al.
2005).
4.1.3 Colon adenomas and adenocarcinoma
Benign mucosal neoplasias of the colon are defined as adenomas. Colon adenomas are
divided into tubular, tubulovillous, and villous adenomas according to their general
structure and histology. Characteristic of colon adenomas is dysplasia, varying from mild
to severe changes, which may precede cancer. In certain diseases, such as familial
adenomatous polyposis (FAP), the bowel contains numerous adenomas due to a gene
mutation, and the patients are at high risk for developing cancer (Kim and Lance 1997).
Sporadic colon cancer progresses in a stepwise fashion from adenoma to carcinoma. In
chronic bowel inflammation, the epithelium is constantly disrupted. Inflammatory cells
intruding the mucosa produce reactive oxygen species, which inhibit DNA repair, leading
to DNA alterations in many genes (Leslie et al. 2003). Mutations as well as methylation of
tumor suppressor genes, such as p53 or adenomatous polyposis coli (APC) (Table 4),
promote uncontrolled cell proliferation and decreased apoptosis of the transformed cells.
Gradually, the tumor cells become resistant to growth inhibition and start invading
(Itzkowitz and Yio 2004).
4.2 Hepatic neoplasias and dysfunction
Liver neoplasias include primary benign and malignant tumors, and metastatic lesions of
malignancies from other organs. In Finland, the three most common primary cancers of
the liver are hepatocellular carcinoma , cholangiocarcinoma, and hepatoblastoma (Table
4). A large number of hepatic neoplasms arise from distant metastases of tumors of other
organs (Salo 2004). Here, we discuss the two most important pediatric liver tumors:
hepatoblastoma and hepatocellular carcinoma. In addition, hereditary tyrosinemia type I, a
metabolic disorder with hepatic involvement leading to liver cirrhosis and hepatocellular
carcinoma, is discussed.
4.2.1 Hepatocellular carcinoma
Hepatocellular carcinoma (Table 4) comprises 23% of pediatric liver tumors (Meyers
2007), but is rarely noted before the age of six years (Isaacs 2007). The fibrolamellar
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variant of HCC occurs mainly in young adults. Risk factors for HCC include chronic viral
hepatitis, autoimmune hepatitis, and metabolic disorders, such as tyrosinemia and
hemochromatosis, all of which may lead to cirrhosis (Meyers 2007). The liver tissue
undergoes repeated cycles of cell death and regeneration. The cells encounter point
mutations and epigenetic changes in their genes, impaired regulation of tumor suppressor
genes, and DNA methylation. Consequently, the genetically altered hepatocytes give rise
to dysplastic cells, which are eventually transformed into tumor cells (Thorgeirsson and
Grisham 2002).
HCC is rather resistant to chemotherapy. Tumor resectability (no metastases, tumor size
<10 cm, unilobularity) carries a relatively good prognosis irrespective of the histologic
type (Salo 2004). HCC tends to disseminate in the veins and lymphatic ducts. Therefore,
metastases are frequently present at the time of HCC diagnosis (Katzenstein et al. 2003).
Elevated levels of serum ?-fetoprotein (S-AFP) are found in up to 74% of patients with
HCC (Marrero and Lok 2004). However, AFP is relatively nonspecific as a tumor marker,
as its serum levels are usually elevated already in hepatitis and liver cirrhosis (Marrero and
Lok 2004).
The proliferative rate of the hepatocytes is accelerated by multiple growth factors, such as
HGF, IGF, and TGF-? (Horiguchi et al. 2002, Thorgeirsson and Grisham 2002). Enhanced
Wnt signaling is implicated in the activation of tumorigenic hepatic stem cells (Table 4)
(Yang et al. 2008). At the same time, the growth control may have deteriorated because of
microsatellite instability or oxidative DNA damage and methylation of tumor suppressors,
e.g. p53, or transcriptional proteins (Thorgeirsson and Grisham 2002). Similarly to
gastrointestinal cancers, in hepatic tumors, the effect of TGF-? is either tumor-suppressing
or -promoting. Mutations in TGF-? receptors have been indicated in HCC (Table 4),
which could explain the loss of the growth inhibitory effect of TGF-? on HCC (Ji et al.
2006, Lu et al. 2008). However, migratory signals are not inhibited by receptor mutations.
TGF-? is therefore a strong promoter of liver carcinogenesis (Jakowlew 2006).
4.2.2 Hepatoblastoma
Hepatoblastoma (Table 4) is an extremely malignant hepatic tumor occurring already in
the fetal period or early childhood (Isaacs 2007). It comprises approximately 43% of
pediatric liver tumors in Western countries. Beckwith-Wiedemann’s syndrome and
familial adenomatous polyposis predispose to hepatoblastoma (Meyers 2007). The tumor
has two anatomic variants. The epithelial type of hepatoblastoma has many subtypes, the
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most common of which is composed of small embryonal or larger fetal-like cells. The
mixed epithelial and mesenchymal variant contains foci of mesenchymal differentiation
(Siopel 2008). The small cell undifferentiated epithelial-type hepatoblastoma has the worst
prognosis (Meyers 2007).
No specific biological markers exist for hepatoblastoma. Regardless that serum AFP is
elevated in 90% of patients with hepatoblastoma (Meyers 2007), its specifity is poor, as
discussed earlier. Moreover, the more aggressive tumors tend to fail to express AFP at the
time of diagnosis. The diagnosis is based on histological assessment of needle biopsy or
liver resection. The most reliable, even curative treatment for hepatoblastoma is
chemotherapy combined with surgery or liver transplantation (Meyers 2007).
Protein expression studies have earlier demonstrated that AFP and ?-1-antitrypsin are
expressed in the tumor tissue itself (Abenoza et al. 1987, Ramsay et al. 2008).
Hepatoblastoma cells have been shown to produce erythropoietin (Epo) in hypoxic
conditions in vitro (Goldberg et al. 1987, Nielsen et al. 1987, Ueno et al. 1989, Rondon et
al. 1991), and Epo has been detected in primary cell cultures as well (Von Schweinitz et
al. 1995). In the fetus, Epo is produced generally in the liver  (Migliaccio et al. 1986). It
has also been reported in a hepatocellular carcinoma (Matsuyama et al. 2000). Recently,
Epo receptors were detected in hepatoblastoma (Trobaugh-Lotrario et al. 2007).
Erythropoiesis is suggested to occur in well-differentiated hepatoblastomas (Emura et al.
1985), but there are no reports on Epo expression in the tumor cells of hepatoblastoma in
vivo.
4.2.3 Tyrosinemia type I
Tyrosinemia type I is a hereditary disease. It is characterized by defective tyrosine
metabolism due to a mutation in the gene coding for fumarylacetoacetate hydrolase
(FAH), which is expressed mainly in the liver and kidneys. The liver is therefore most
frequently affected by tyrosinemia type I. Defects in tyrosine metabolism lead to the
accumulation of tyrosine pathway metabolites in the liver, which inhibit normal hepatic
function. The accumulated metabolites possess mutagenic potential and promote
disruption and malignant growth of liver parenchymal cells (Ashorn et al. 2006).
Patients with tyrosinemia type I have a poor prognosis and die during early childhood
without treatment (Ashorn et al. 2006). Oxidative stress leads to liver fibrosis and
cirrhosis, ductular proliferation, and dysplasia. The patients are also at high risk for
manifesting HCC (Russo et al. 2001).  Therefore, liver transplantation, being curative, is
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indicated for the treatment of tyrosinemia type I (Ashorn et al. 2006). Surveillance of the
patients prior to liver transplantation is extremely important because of the high incidence
of malignancy. Serum AFP can be used in monitoring early cancer lesions, but cautious
interpretation is necessary due to false-negative/-positive results. New markers for early
detection of HCC in tyrosinemia type I are therefore needed.
5 Mouse models for gastrointestinal inflammation and tumorigenesis
Mice and humans have many anatomical and physiological similarities in their
enterohepatic systems. The most significant differences are found in the stomach, the
proximal third of which in mice is lined by squamous epithelium rather than the glandular
epithelium found in humans. The oxyntic glands are thus present only in the corpus of the
murine stomach. The murine cardia comprises only a few glands, in which dysplastic
lesions are often initiated. Another drastic difference in the gastrointestinal anatomy is the
size of the cecum, which is enlarged in mice (Rogers and Fox 2004).
In humans, Helicobacter pylori is associated with chronic gastritis and the development of
gastric lesions and, in some instances, cancer. In mice, Helicobacter spp. are the only
proven bacteria to induce gastric adenocarcinoma and mucosal-associated lymphoid tissue
(MALT) lymphoma (Rogers and Fox 2004). Moreover, C57BL is the best strain to display
Helicobacter-induced gastritis due to the strongest immunogenic reaction leading to
gastric hyperplasia and dysplasia. The murine model closely mimics the progression of
gastritis-related cancer in humans (Rogers and Fox 2004). Carbonic anhydrase 9 is
implicated in the regulation of proliferation and cancer cell invasion in the GI tract, and
mice with targeted mutation of Carbonic anhydrase 9 -/- develop gastric hyperplasia
(Parkkila 2008). Other mouse models developing gastric tumors are, for example, TFF-1
knockout mice (Lefebvre et al. 1996) and Smad4 +/- heterozygous mice (Table 5) (Xu et
al. 2000).
The animal models currently used for IBD and celiac disease present only part of the
features characteristic of the disease pathology in the intestine and are therefore somewhat
unreliable for human disease. Colitis can be induced with chemicals such as
trinitrobenzene sulfonic acid (TNBS) and dextran sodium sulfate (DSS) (Te Velde et al.
2006, Kawada et al. 2007). The gene expression profiles of the intestines of these mice
resemble those of human IBD (Te Velde et al. 2007). Targeted mutation of several genes,
e.g. TGF-?1, Smad3 and Muc2 (Table 5), predisposes the murine intestine to
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inflammation and may lead to tumor formation (Shull et al. 1992, Kulkarni et al. 1993,
Rogers and Fox 2004). Mouse models with mutations in the TGF-? signaling pathway
appear to be strongly associated with colon carcinoma and further with cancer invasion
and incidence of metastasis (Takaku et al. 1998, Zhu et al. 1998, Engle et al. 1999).
Infectious murine liver cancer models have been generated successfully by mutating the
murine viral genes for hepatitis B and C (Table 5). In some instances, the viral transgenes
fail to induce hepatitis due to immunotolerance towards viral antigens developing already
during the embryonal period (Rogers and Fox 2004). Transgenic mice models with an
increased risk for HCC also exist (Smit et al. 1993, Deane et al. 2001). Recently, mouse
models have been generated for hereditary tyrosinemia type I (Table 5) (Nakamura et al.
2007a). For hepatoblastoma, the present in vivo models are mice with spontaneous tumors
or those with implanted human hepatoblastoma xenograft.
Table 5. A selection of mouse models for the pathogenesis of digestive diseases.
Tissue Strain Transgene/infectious agent Pathology
Stomach
C57BL High dietary salt gastric atrophy
Balb/c N-nitroso carcinogens adenocarcinoma
Balb/c Helicobacter spp. gastritis, MALT lymphoma
C57BL Helicobacter felis gastritis, adenocarcinoma
FVB Gastrin transgene adenocarcinoma
C57BL/129Sv Targeted mutation TFF1 -/- adenocarcinoma
C57BL/129Sv Targeted mutation Smad4 +/- gastric polyps, adenocarcinoma
C57BL Targeted mutation Ca9 -/- * gastric hyperplasia
Intestine
Balb/c Trinitrobenzene sulfonic acid colitis
C57BL Dextran sodium sulphate colitis
129Sv Targeted mutation TGF-?1 -/-
+ Helicobacter hepaticus
colitis, adenocarcinoma
129Sv Targeted mutation Smad3 -/-
+ Helicobacter hepaticus
colitis, adenocarcinoma
129Sv Targeted mutation Muc2 -/-
+ Helicobacter hepaticus
colitis, adenocarcinoma
Liver
C57BL HBV or HCV transgenes hepatocellular carcinoma
C57BL Cyclin D1 transgenic mice hepatocellular carcinoma
A/JCr Helicobacter hepaticus hepatocellular carcinoma
C57BL Targeted mutation Fah -/- tyrosinemia type I
Abbreviations: MALT, mucosal-associated lymphoid tissue; TFF, trefoil factor; Ca9, carbonic
anhydrase 9; TGF, transforming growth factor; HBV, hepatitis B virus; HCV, hepatitis C virus
* (Gut et al. 2002), the rest of the data is collected from the Jax® Mice Database
www.jaxmice.jax.org and recent reviews (Pritchard and Przemeck 2004, Rogers and Fox 2004,
Nakamura et al. 2007a).
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The gastrointestinal mucosa and liver parenchyma are constantly renewing tissues. To
date, the factors governing the complex cell programming are largely unelucidated. A
better understanding of normal tissue regeneration and the pathomechanisms of impaired
growth is needed. The aims of this study were as follows:
1. To determine the expression of GATA-4, GATA-5, and GATA-6 in the gastrointestinal
tract and liver during normal development and in mature tissues, and to investigate GATA
factors in the regulation of intestinal genes.
2. To investigate the role of GATA-4 in gastrointestinal inflammation and its relationship
with TGF-? signaling in tissue repair.
3. To define the expressions of GATA-4 and GATA-6 in benign and malignant tumors of
the human gastrointestinal tract.
4. To characterize the expressions of GATA-4, GATA-6, and the Friends of GATA in
malignant hepatic tumors and disorders in children and adults, and to determine the
expression of erythropoietin in relation to its possible upregulator GATA-4.
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PATIENTS, SAMPLES, AND METHODS
1 Tissue samples of patients (III-V)
The gastrointestinal specimens were obtained during esophagogastroduodenoscopy,
colonoscopy, or intestinal resections. Liver samples were acquired from needle biopsies,
tumor resections, or liver explants. The fetal hepatic samples were from autopsy
specimens. Serum samples were collected from patients with hepatoblastoma. All samples
(Table 6) were fixed in formalin or frozen in liquid nitrogen and stored at -80°C to await
further use. Fetal and adult liver RNA and ready-to-use Western membranes were
purchased from BioChain (Hayward, CA, USA).
2 Murine samples (I, II, V)
Gastrointestinal and hepatic samples from normal newborns, 7, 12, 14, 15, 18, or 21 days
old and from adults were dissected from mice raised in the Test Animal Center of the
University of Helsinki. NMRI, C57Bl/6J, and 129/Ola mixed background mice were
killed by cervical dislocation. The gastrointestinal tract and liver were dissected and fixed
in 4% paraformaldehyde (PFA). In addition, the FVB/N mice with a liver fatty acid
binding protein (Fabpl) transgene with mutagenized GATA or HNF-1 sites, and ROSA26
mice chimeric for Gata4 were produced in St. Louis, MO, USA, as previously described
(Jacobsen et al. 2005). The animal studies were approved by the Washington University
Institutional Animal Care and Use Committee and by the local authority at the University
of Helsinki following the guidelines of the National Research Council.
3 Immunoperoxidase staining (I–V)
The immunoperoxidase staining was performed following the protocol outlined in detail in
studies I-IV. The primary antibodies are presented in Table 7. To visualize binding of the
antibody, 3,3’-diaminobenzidine (Sigma-Aldrich, St. Louis, MO, USA) was used. In
double immunostaining, a Vector SG substrate kit (Vector Laboratories, Burlingame, CA,
USA) indicated the binding of the second primary antibody. The specificity of the staining
was assessed using preimmune serum or PBS instead of the primary antibody.
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Table 6. Patients with normal and inflammatory gastrointestinal samples, gastrointestinal
and hepatic tumors, and serum samples used in the study.
Human samples were originally collected for diagnostic purposes in the University Central
Hospitals of Helsinki and Tampere. The study was approved by the Ethics Committees of both
University Hospitals, the Finnish National Authority of Medicolegal Affairs, and the Ministry of
Social Affairs and Health.
Sample Patient
n (children)
Age (years)
median (range)
Method Study
Tissue
Esophagus
Barrett’s esophagus 9 (0) 68 (55–83) IHC III
Stomach
normal 11 (6) 15 (1.0–91) IHC, ISH III, IV
gastritis,
intestinal metaplasia 7 (0) 56 (49–73) IHC III
neuroendocrine cell
hyperplasia 3 (0) 54 (49–69) IHC III
carcinoid tumor 1 (0) 63 IHC V
Duodenum
normal 42 (36) 6.0 (0.3–73) IHC, ISH III
celiac disease 17 (17) 1.5 (0.3–15) IHC V
Ileum
normal 16 (7) 31 (3.9–76) IHC, ISH III, IV
Crohn’s disease 4 (4) 13 (12–15) IHC, ISH IV
ulcerative colitis 3 (3) 8.9 (6.1–13) IHC, ISH IV
carcinoid tumor 8 (0) 64 (44–86) IHC V
Colon
normal 26 (19) 12 (0.1–76) IHC, ISH III, IV
Crohn’s disease 11 (4) 24 (12–62) IHC, ISH IV
ulcerative colitis 12 (3) 46 (3.9–62) IHC, ISH IV
lymphocytic colitis 5 (0) 64 (49–82) IHC, ISH IV
carcinoid tumor 8 (0) Not determined IHC
adenoma 4 (0) 60 (28–77) IHC III
adenocarcinoma 12 (0) 72 (41–87) IHC, ISH, NB III
Liver
normal – fetus 3 (2) 19 wk (12–31)wk IHC, WB,
RT-PCR
V
normal – adult 1 (0) 64 WB, RT-PCR V
hepatoblastoma 14 (14) 4.3 (0.2–9.1) IHC, WB,
RT-PCR
V
hepatocellular
carcinoma 13 (6) 36 (2.0–75) IHC, WB,
RT-PCR
V
tyrosinemia type I 10 (10) 1.4 (0.4–6.0) IHC V
Serum
hepatoblastoma 4 (4) 1.8 (0.6–11) ELISA V
Abbreviations: IHC, immunohistochemistry; ISH, in situ hybridization; WB, Western blot; NB,
Northern blot; ELISA, enzyme-linked immunosorbent assay
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4 In situ 3’-end labeling (TUNEL) (IV)
DNA fragmentation of the apoptotic cells was detected by TUNEL assay, as described in
study IV. Tissue sections were labeled with terminal transferase enzyme and
digoxigenin-11-ddUTP (Roche Diagnostics, Basel, Switzerland) nucleotides.
Fragmentation was visualized by 3,3?-diaminobenzidine (Sigma-Aldrich).
5 Radioactive mRNA in situ hybridization (I, III, IV)
Deparaffinized tissue sections or cryosections (5 ?m) fixed in 4% PFA were subjected to
mRNA in situ hybridization using sense and antisense riboprobes for GATA-4 and
GATA-6, and FABPL-labeled with 1.2 x 106 cpm of [33P] (1000-3000 Ci/mmol,
Amersham Biosciences, Arlington Heights, IL, USA). The slides were developed after 1
and 2 weeks of autoradiography and counterstained with hematoxylin.
6 Northern blot hybridization (V)
Total RNA was isolated from the frozen tissues. One microgram of RNA was subjected to
electrophoresis on a 1% agarose gel and transferred onto nylon membranes. The GATA-4
complementary DNA probe was labeled with [32P]deoxy-CTP (3000 Ci/mmol,
Amersham) and was thereafter used for hybridization of the membranes. Hybridization
signals were detected by autoradiography. A specific probe for ribosomal 28S mRNA
served as a loading control.
7 Cell culture stimulations and transfections (I, II, IV, V)
HepG2 (human hepatoblastoma), HeLa (human cervical cancer), LLC-PK1 (porcine renal
epithelium), and Caco-2 (human colon cancer) cells were purchased from American Type
Culture Collection or obtained from the Universities of Helsinki and Washington. For
stimulation experiments, Caco-2 cells were plated at a density of 5 × 105 cells/cm2.
Growth medium was replaced by serum-free media 20 h prior to stimulation experiments
performed 6 or 12 days after plating. The cells were stimulated with recombinant human
TGF-?1 (10 or 50 ng/ml), IL-6 (20 ng/ml), or TNF-? (20 ng/ml) and collected either 6 or
24 h after the beginning of stimulation. Differentiation was assayed with intestinal cell
differentiation marker sucrase-isomaltase detected by RT-PCR.
Transient transfections were performed either by calcium phosphate precipitation (Divine
2003) or by Lipofectamin 2000® at a cell density of 40–60%. The cells were transfected
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with Fabpl and transcription factor plasmids, and a pGL3 control plasmid for
normalization of the experiments. The transfections were analyzed by radioimmunoassay
and luciferase detection, and protein binding assayed 48 h posttransfection. Additionally,
Caco-2 cells were transfected with human GATA-4 silencing RNA. The cells were
collected on days 6, 10, and 12 (3, 7, and 9 days posttransfection) and subjected to RNA
extraction.
8 Western blot (IV, V)
Protein from tissue samples or cell cultures was extracted using a commercial
NucleoSpin® RNA/protein extraction kit (Machery-Nagel, Düren, Germany). The
detailed protocol for Western detection is given in study IV. The primary antibodies are
presented in Table 7.
Table 7. Primary antibodies and probes used in the study.
Gene/Protein Producer Catalog
number
Dilutions
IHC / WB
cDNA/riboprobe Study
GATA factors
GATA-4 Santa Cruz sc-1237 1:200/1:1000 RT-PCR (IV); in
situ (III); NB
(Heikinheimo ´94)
I – IV,
UD
GATA-5 Santa Cruz sc-7280 1:200/ - - I – II
GATA-6 Santa Cruz sc-9055 1:50/1:500 RT-PCR(IV);
in situ (III)
I – IV,
UD
GATA cofactors
FOG1 Santa Cruz sc-9361 1:100/ - - UD
FOG2 Santa Cruz sc-10755 1:50/ - - UD
TGF-? signaling
TGF-? Santa Cruz sc-146 1:200/ - - IV
Smad2 Zymed 51-1300 1:100/1:500 RT-PCR (IV) IV
Smad3 Zymed 51-1500 1:100/1:2500 RT-PCR (IV) IV
Smad4 Santa Cruz sc-7966 1:100/1:1000 RT-PCR (IV) IV
Apoptosis and proliferation
Bax BD Biosciences 554104 1:1000 - IV
Bcl-2 Santa Cruz sc-492G 1:400 RT-PCR (IV) IV
Ki67 Dako - 1:50/ - - IV
Other
Chromogranin A Santa Cruz sc-1488 1:50/ - - III
Erythropoietin Santa Cruz sc-7956
sc-1310
1:100
/1:1000
RT-PCR
(Juul ´98)
UD
H+/K+ -ATPase ? Calbiochem 119102 1:50/ - - III
H+/K+ -ATPase ? Affinity
Bioreagents
MA3-923 1:50/ - - III
Ihh Santa Cruz sc-1196 1:50/ - - III
Actin Santa Cruz sc-1616R - /1:10000 - IV, UD
?-actin - - - RT-PCR (IV) IV
FABPL - - - in situ (I) I
sucrase-isomaltase - - - RT-PCR (IV) IV
Abbreviations: IHC, immunohistochemistry; WB, Western blot; UD, unpublished data
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9 Reverse transcriptase PCR (I, II, IV, V)
The total RNA (1 ?g) from tissue samples and cell cultures was reverse-transcribed (RT)
and further subjected to PCR. For GATA-4, a semiquantitative PCR was performed by
introducing the final extension after four different cycles. The PCR products were
electrophoresed and visualized under UV light. The band sizes were compared with Hae
or Hind markers. The intensities and areas of each band were analyzed using a Quantity
One program (Bio-Rad Laboratories Inc., Hercules, CA, USA). ?-actin was used as an
internal control for mRNA levels.
10 Enzyme-linked immuno sorbent assay (ELISA)
Serum samples of patients with hepatoblastoma were collected during various phases of
tumor diagnosis and treatment. The EPO ELISA kit (DRG Instruments, Marburg,
Germany) was used in the detection of serum Epo following the manufacturer’s
instructions. The biotinylated Epo antibody was detected with a peroxidase-labeled
antibody and further subjected to tetramethylbenzidine. The reaction was terminated with
sulfuric acid, and the optical densities were measured spectrophotometrically at 405 nm.
11 Microscopic evaluation (I-V)
Radioactive mRNA in situ hybridization slides were assessed under a dark field light
microscope (Leica DMRXA microscope). Positivity of the sample was evaluated by
comparing the radioactive signal of the tissue to the background signal. The TUNEL assay
and immunoperoxidase stainings were evaluated under a light field microscope (Leica)
independently by at least two researchers.
12 Statistical analysis (I, II, IV, V)
The numeric values obtained from cell line and tissue analyses were inspected using
SPSS. Mean values with standard error of the means were calculated. P-values by
Student’s t-test indicated the significance of findings.
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1 GATA factors in gastrointestinal and liver morphogenesis and tissue-specific gene
expression
Gastrointestinal morphogenesis results from a delicately controlled interplay of cell
interactions, epithelial-mesenchymal crosstalk, and the complex regulatory network of
signaling peptides and transcription factors. The regulatory proteins important in prenatal
development continue to have vital roles in the mature gastrointestinal tract in maintaining
stem cell populations, determining cell fate, programming differentiation, and
coordinating tissue renewal (Leedham et al. 2005). Growing evidence suggests that
GATA factors play crucial roles in gastrointestinal morphogenesis and the maintenance of
the normal epithelium of the mature alimentary tract. We describe here the expression
patterns of GATA-4, GATA-5, and GATA-6 in the murine and human gastrointestinal
tract and liver and discuss their likely target genes and tasks in the digestive tissues.
1.1 Developing murine gastrointestinal mucosa and liver (I, II, V)
One of the first studies on GATA factors in the gut (Arceci et al. 1993) demonstrated
GATA-4 mRNA in the gastrointestinal tract of the mouse embryo. The study was soon
followed by other investigations indicating GATA factors in the developing and mature
murine gut (Morrisey et al. 1996, Suzuki et al. 1996, Dimaline et al. 1997, Morrisey et al.
1997). GATA-4 was found to be among the first transcription factors binding to chromatin
in order to potentiate the initiation of endodermal differentiation in cooperation with HNF-
3 (Bossard and Zaret 1998, Cirillo et al. 2002). Other studies have revealed that GATA-4
and GATA-5 prefer the more differentiated intestinal cells, whereas GATA-6 is
downregulated during cell maturation in vitro (Gao et al. 1998). We demonstrated
intervillous expression of GATA-4 and GATA-6 in the intestines of postnatal mice,
suggesting the association of GATA factors with the proliferation and initiation of
differentiation of precursor cells. These events are presumably also affected by epithelial-
mesenchymal interactions. We detected GATA-4 and GATA-6 both in the immature
epithelial cells of the developing postnatal mouse gut and in the mature intestinal
enterocytes of adults. The GATA expression pattern depended on the developmental stage
and the proximal-distal axis as well as on individual cell types.
While GATA-4 and GATA-6 presented rather stable levels of expression in the postnatal
small intestine (Figure 1 in study II), the expression of GATA-5 was restricted to a
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very limited time window during the suckling period, as explained in detail later. After the
suckling-weaning transition, the expression of GATA-5 was restricted to relatively small
areas in the stomach, presumably to the cardia (Table 8 and Figure 7). The presence of
GATA-5 in this particular area could be due to its role as a regulator of mucins (Ren et al.
2004), which are found in cardiac glands. Mucins are produced to protect the
gastroesophageal junction from acidic fluids that may sometimes flow upstream and
disrupt the squamous epithelium. GATA-5 is thus likely to play a protective role in the
normal murine stomach.
Figure 7. The expressions of GATA-4, GATA-5 and GATA-6, and Friends of GATA in
murine stomach.
GATA-4, GATA-6 and FOG-2 presented a robust expression pattern in the adult murine stomach.
Immunoreactivity for GATA-4/6 was detected in the gastric glands as well as the neck and surface
cells, whereas FOG-2 was generally expressed in the neck region. The mucosa was devoid of
FOG-1, but a limited staining pattern for GATA-5 was detected in the cardia. The arrows indicate
the nuclear positivity. Scale bar for 200 ?m.
The ultimate importance of GATA factors in gut morphogenesis have long remained
poorly elucidated. The difficulty lies in the GATA-4 and GATA-6 knockout model mice,
which die until E9 because of lethal defects in early endoderm and heart formation (Kuo et
al. 1997, Molkentin et al. 1997, Narita et al. 1997a, Koutsourakis et al. 1999). Due to the
variety of organs expressing GATA factors, it was earlier thought that GATA factors
alone are not crucial for the regulation of cell type specification and determination in the
endoderm. Mesodermal GATA-4 deficiency is, indeed, counteracted by endodermal
GATA-4 signals in chimeric mice presenting normal heart and foregut development
(Narita et al. 1997b). Recent studies on mice chimeras (Jacobsen et al. 2005) and
intestinal Gata4 silencing (Bosse et al. 2006) have indicated the importance of GATA-4
for tissue-specific cell differentiation in the gut. We could not, however, detect
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morphological changes in the Gata4-deficient enterocytes of mice chimeric for Gata4
compared with wild-type intestinal epithelial cells. The controversy could be explained by
the villin promoter-mediated method (Bosse et al. 2006) being more accurate in intestinal
gene deletion and thus serving as a better model for organ-specific studies than the
chimeras, which always have tissue with a normal gene pattern within the same organ.
GATA factors are unlikely to function alone in the gut, and GATA cooperation has been
indicated with multiple other factors such as Cdxs and HNFs (Escaffit et al. 2005). FOG-1
and FOG-2 are also known as cofactors of GATA proteins. Although GATA-4 is
generally considered to cooperate with FOG-2, FOG-1 is suggested to direct gastric
development together with GATA-4 in mouse embryos (Jacobsen et al. 2005). In the adult
murine gastric epithelium, we detected FOG-2 rather than FOG-1 (Figure 7). Interestingly,
FOG-2 was also present in the duodenal Brunner glands positive for both GATA-4 and
GATA-6 (unpublished data). Challenging the earlier studies (Cantor and Orkin 2005), our
findings suggest that in contrast to mouse embryos, FOG-2 is the predominant FOG
protein in the adult mouse stomach.
In the murine liver, GATA-4 and GATA-6 participate in the embryonal development.
GATA-4 potentiates gene expression during the onset of hepatogenesis (Bossard and Zaret
1998). GATA-4 cooperates with HNF-3 (Fox3A) to stimulate the albumin gene in liver
progenitor cells (Cirillo et al. 2002). Both GATA-4 and GATA-6 are essential for the
expansion of the liver bud (Zhao et al. 2005, Watt et al. 2007). Later on, their expression
is robust in the fetal mouse hepatocytes (Dame et al. 2004) Within adult mouse
hepatocytes, we observed merely GATA-6, whereas GATA-4 was implicated in the other
parenchymal cell types resembling sinusoid endothelial cells or monocyte-derived Kupffer
cells. GATA-5 was not detected in the murine liver (Table 8).
Table 8. GATA expression in the murine
adult gastrointestinal tract and liver.
- no expression,
+ expression in single cells or small areas,
++ expression in large areas
GATA-4 GATA-5 GATA-6
Stomach
cardia ++ ++ +
corpus ++ + ++
pylorus ++ + ++
Small intestine
++ - ++
Large intestine
- - ++
Liver
hepatocytes - - ++
Kupffer/
endothelial cells ++ - -
bile duct cells - - ++
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1.2 Human digestive system (III-V)
Although GATA factors are important in murine gut embryogenesis, relatively few
investigations have elucidated GATA-4 and GATA-6 expression in the normal human
alimentary tract. The expression of GATA-5 protein remains poorly enlightened, as no
suitable antibodies exist for its detection in human tissue. We found distinct cell and tissue
type specificity for GATA-4 and GATA-6 in human gastrointestinal mucosa. The
expression patterns were very similar to those in mice (Figures 1 and 2 in study III).
GATA-6 was indicated along the whole gastrointestinal tract, especially in the
compartment comprising undifferentiated cells capable of proliferation. GATA-4 was
mostly confined to absorptive enterocytes and a gradient of intensity appeared along the
crypt villus axis. The strongest GATA-4 expression was localized to the region directly
above the transitional zone, where differentiation of stem cell progenitors is   initiated. In
the human Caco-2 cell line, we detected GATA-4 upregulation during TGF-?1-induced
intestinal cell differentiation (Figure 8). In contrast to an earlier study (Gao et al. 1998),
GATA-6 expression was strongly independent of the differentiational status of the cells.
Furthermore, the expression levels of GATA-4 and GATA-6 remained relatively stable
from birth until adulthood throughout the gastrointestinal mucosa.
Figure 8. Involvement of GATA-4 in the
differentiation and apoptosis of intestinal cells
in vitro.
(A) The spontaneous differentiation of Caco-2
cells was enhanced by stimulating the cell
cultures with 50 ng/ml of TGF-?1 on days 6 and
12. The differentiation was verified by sucrase-
isomaltase PCR analysis. RT-PCR revealed,
along with the differentiation, an upregulation of
GATA-4, which was further enhanced by TGF-
?1. Bars (mean + S.E.M.). * = P<0.05, by
Student’s t-test vs. control. (B) The transfection
of Caco-2 cells with GATA-4-silencing mRNA
was introduced three days after plating. The
preliminary results indicated a slight
downregulation of Bcl-2 in the cells with silenced
GATA-4, which did not seem to affect sucrase-
isomaltase expression. ?-actin was used as an
internal control for mRNA levels.
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The immunodetection of a GATA-related, cancer-associated factor, Ihh, revealed a
correlation between GATA-6 and Ihh. Both were indicated in gastric glands and colon
mucosa (Figure 2 in study III), although the expression of Ihh was rather limited. Ihh is
suggested to maintain the intestinal stem cell compartment. In the colon, it is required for
normal epithelial differentiation (Ramalho-Santos et al. 2000). Ihh is speculated to
stimulate both proliferation and differentiation within the same tissue in humans (Watt
2004). In mouse knockouts for Ihh, the intestinal villi of embryos are reduced in size (Lees
et al. 2005). We thus speculate that GATA-6 could exert some of its cellular functions
through its probable downstream factor Ihh.
GATA-4 and GATA-6 are known to contribute to hepatic development during murine
embryogenesis. In humans, GATA-4 expression is indicated in the fetal liver, mimicking
the pattern found in mice (Dame et al. 2004). Additionally, GATA-4 is indicated in
hepatic stem cells characterized by Epo expression (Dame et al. 2004). The
downregulation of GATA-4 in hepatocytes occurs before birth (unpublished data) or
perinatally. In adults, GATA-4 was previously reported only in the epithelial cells
surrounding the biliary ducts (Dame et al. 2004). Interestingly, we found GATA-4 in
Kupffer cells. GATA-4 has not earlier been detected in cells of hematopoietic origin.
1.3 Regulation of digestive functions (I, II, IV)
GATA-4, GATA-5, and GATA-6 are implicated in the regulation of a large number of
genes within the gastrointestinal tract and liver (Table 3). Our human and murine studies
demonstrated cell type-specific expression for GATA-4, GATA-5, and GATA-6, which in
general correlated with previous gene expression studies (Figure 1 in study I and Figure 3
in study III). For example, GATA-4 and GATA-6 were detected in murine (Figure 7) and
human (Figure 3 in study III) gastric glands comprising parietal cells, which have earlier
been shown to express a GATA-4/6-regulated H+/K+-ATPase (Maeda et al. 1996). Other
relevant GATA-regulated genes in the gastric mucosa are the ones encoding
gastroprotective mucins and trefoil factors that are expressed especially in the glands and
surface epithelial cells of the cardia (Dignass and Sturm 2001), in which we showed
protein expression for each of the endodermal GATA proteins (Figure 1 in study I and
Figure 4 in study III).
GATA-4 and GATA-6 have widely been considered to be associated with the regulation
of the digestive function of the gut epithelium. Especially GATA-4 is suggested to
enhance intestinal cell determination (Gao et al. 1998); it regulates a number of intestine-
specific genes (Table 3) and is considered to maintain a small intestine-specific enterocyte
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phenotype in mice (Bosse et al. 2006). GATA-5 and GATA-6 are also indicated in the
gene regulation of the alimentary tract and liver (Table 3). However, in the intestine they
affect gene regulation cooperatively with other factors rather than by themselves. HNF-1?
and Cdx-2 proteins interact together with GATA-4, forming a complex that activates the
sucrase-isomaltase gene (Boudreau et al. 2002). Our in vitro study demonstrated that
GATA-4/5/6 in concert with HNF-1? activates the Fabpl gene expressed in murine
hepatocytes and enterocytes (Figure 9). Such cooperation has earlier also been indicated in
the regulation of the lactase gene (Troelsen 2005). Furthermore, we demonstrated that a
mutation in the GATA binding site of the Fabpl promoter does not affect the functionality
of GATA proteins due to their ability to mediate their effect via cooperation with HNF-1?.
GATA factors also have cooperative functions with each other. Our in vitro experiments
suggest that when present in pairs GATA factors upregulate Fabpl gene expression more
markedly than when alone (Figure 9).
In the mouse postnatal intestine, the upregulation of GATA-5 coincides with the
enhancement of lactase phlorizin hydrolase (Figure 9), which has its peak expression
during the suckling period (Troelsen 2005). Sucrase-isomaltase, by contrast, is first
detected at two weeks of age, but increases after weaning (Krasinski et al. 1994). The
postnatal gastrointestinal tract also undergoes other changes, probably correlating with
GATA-5. In addition to the intrinsic timing mechanism of cell specification and
differentiation, glucocorticoids are likely to elicit intestinal maturation and gene
expression via transcription factor-mediated regulation. Glucocorticoids have clinical
relevance in the management of preterm infants. Glucocorticoids upregulate GATA-4 in
vivo (Oesterreicher and Henning 2004), but the hormonal impact on GATA-5 is still
unexplored.
Similarly to the alimentary tract, the liver encounters functional alterations during
postnatal development. One of the most important changes is the switching of Epo
production from the liver to the kidney. The regulator of erythropoiesis, Epo, is
downregulated in the postnatal liver equally to GATA-4, which has been shown to
regulate the Epo gene in vitro (Dame et al. 2004). Although Epo is related to the
generation of hematopoietic cells, its association with GATA-4 is not surprising since both
factors are expressed in hepatocytes, which are of endodermal origin. Epo expression has
also been shown in Kupffer cells, where FOG-1 was expressed. FOG-1 has earlier been
detected in hematopoietic cells of the murine liver, where it is expressed already at E12.5
(Cantor and Orkin 2005). Instead of GATA-4, the main target for the function of FOG-1 is
likely GATA-1, which is expressed in hematopoietic cells of the fetal liver, but is
downregulated after the second trimester (Matsuda et al. 1994, Dame et al. 2004).
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Consequently, GATA-1 has not been reported in the human adult liver. Thus, the presence
of FOG-1 along with GATA-4 in human adult Kupffer cells could be related to their
cooperative function in Epo gene regulation.
             Figure 9. The correlation between GATA
             expression and the intestinal enzymes in
             the suckling mice.
             (A) GATA-5 was upregulated postnatally but
             downregulated until suckling-weaning
             transition in murine small intestine detected
             by immunohistochemistry. Scale bar for 200
             ?m. (B) The downregulation of GATA-5
during weaning coincided with the diminishing lactase phlorizin hydrolase (LPH)1 levels, while
the sucrase-isomaltase protein (SI) is first detected at the time of the downregulation of GATA-5
during the suckling-weaning transition3. + indicates low/moderate expression, ++ is for robust
expression. (C) During the suckling period the GATA-4/6 expression was located to the
intervillous region at the base of the epithelium while GATA-5 preferred the tips of the
lengthening villi. Its expression coincided with that of LPH2 and liver fatty acid binding protein
(FABPL)1. (D) The in vitro studies indicated that GATA factors may cooperatively activate the
Fabpl transgene. Additionally, hepatocyte nuclear factors (HNF)-1? and -1? activateted Fabpl in
concert with each of the GATA factors, of which GATA-4 presented the most powerful effect
(GATA-5/6 not shown). Bars (mean + S.E.M.) present the fold activation compared to
unstimulated controls. 1 (Rubin et al. 1989), 2 (Troelsen 2005), 3 (Tung et al. 1997)
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2 Mucosal inflammation and GATA expression in the gastrointestinal tract
In inflammation, enhanced intrinsic immune defense mechanisms disturb the mucosal
regeneration (Brittan and Wright 2002). Considering the vigorous proliferation of the
immature precursor cells and the accelerated cell turnover, the maintenance of mucosal
homeostasis in inflammation requires extremely delicate regulation.
2.1 Maintenance of mucosal homeostasis (IV)
The Wnt signaling pathway is involved in the regulation of homeostasis within the
mucosal stem cell compartment along with Notch signaling. The proliferative effects of
Wnt signaling on crypt progenitors are related to the cell cycle factors c-Myc and cyclin
D1 (Gregorieff and Clevers 2005). The Wnt-Notch signaling pathways are known to direct
the lineage choice of precursor cells; Notch drives the cells towards an absorptive cell
phenotype, whereas Wnt signaling instructs the cells to develop features of a secretory
cell. The Wnt function generally occurs in the crypts, which are influenced by epithelial-
mesenchymal crosstalk due to the subepithelial myofibroblasts that produce mesenchymal
Wnt signals (Gregorieff and Clevers 2005). The regulation of the Wnt pathway remains
largely obscure. GATA-6 has been shown to upregulate Wnt2 in the embryonic heart
(Alexandrovich et al. 2006), whereas in gastric cancer GATA-6 is indicated in the
regulation of Wnt8b (Katoh and Katoh 2007). We demonstrated its expression in mucin-
secreting intestinal Goblet cells (Figure 3 in study III). GATA-6 could, thus, be involved
in the regulation of Wnt signaling in the colon. In IBD, although Wnt proteins are
upregulated, the target gene expression of Wnts remains stable (You et al. 2008). In our
study, the role of GATA-6 in IBD was indifferent.
TGF-? is suggested to antagonize Wnt signaling in the intestine (Gregorieff and Clevers
2005). It is thus not surprising that we did not detect GATA-4 in cells of the secretory
lineage. TGF-?1 is one of the key regulators of epithelial regeneration. It is known to
induce cell differentiation, epithelial restitution, and healing. Impaired TGF-? signaling
leads to severe colitis in Smad3 -/- mice (Yang et al. 1999). Decreased levels of TGF-?
due to the resection of the appendix, which consists of  lymphatic tissue secreting TGF-?,
is also considered to increase the risk for IBD (Loftus 2004). TGF-?1 is upregulated in
both the epithelium and inflammatory cells of the lamina propria of celiac disease
(unpublished results) (Hansson et al. 2002) and inflammatory bowel mucosa (Figure 10)
(Babyatsky et al. 1996). It is suggested to counteract the destructive changes occurring in
the inflamed mucosa in order to maintain the normal tissue architecture. We propose that
TGF-?1 exerts part of its regenerative function via the gene regulatory protein GATA-4.
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2.2 GATA factors in the regulation of cell proliferation, migration, and
differentiation (IV, V)
In intestinal inflammation, proliferation of stem cells is often dramatically induced,
leading to hyperplasia of the crypt compartment (Figure 5 in study IV) (Beck and
Podolsky 1999). GATA-6 has earlier been thought to contribute to proliferation (Gao et al.
1998). However, the expression level of GATA-6 changed in neither celiac disease nor
inflammatory bowel samples, indicating that it is not involved in inflammation-related
induction of proliferation (Figure 2 in study IV). GATA-4, by contrast, was enhanced in
intestinal inflammation (Figure 10).
Figure 10. GATA-4 expression is altered in intestinal inflammation and correlates with the
upregulation of TGF-?1.
GATA-4 was not detected in normal bowel mucosa (B) but was enhanced in the crypts of the
inflammatory bowel (D) concomitantly with TGF-?1 (D’). GATA-4 was robust in the epithelial
lining of the normal duodenal villi. However, the crypts expressed relatively little GATA-4 (A). In
celiac disease, even though the GATA-4 expressing villi were destructed, the duodenal samples
devoid of proper enterocyte population presented abundant GATA-4 expression, as well (C).
Unlike in normal duodenum, GATA-4 positivity was indicated in the deepened crypts, expressing
TGF-?1 (C’). Scale bar for 200 ?m.
The stem cells lie near the bottom of the crypts. When stimulated, the proliferating cells
start to migrate upwards. By the time the progenitors reach the transition zone, they lose
their ability to further proliferate. At this point, the cells are programmed to differentiate
into a certain cell phenotype and to move up along the villus epithelium (Brittan and
Wright 2002). We detected GATA-4 in the area of transitory cells. Considering that cell
differentiation and migration are induced in both celiac disease and IBD due to rapid
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epithelial healing, GATA-4 upregulation could be explained by its involvement in the
induction of cell fate determination and migratory signaling.
GATA-4 mediates TGF-?-induced gene activation in intestinal cells (Belaguli et al. 2007)
as well as in human granulosa and heart cells in vitro (Brown et al. 2004, Anttonen et al.
2006). While TGF-?1 is known to be induced in intestinal inflammation, we analyzed
GATA-4 along with TGF- ? signaling in tissue samples of patients with celiac disease or
IBD. In addition, in vitro studies were carried out to support the expression data. We
found upregulated GATA-4 in the intestinal Caco-2 cell lines stimulated with TGF-?1
(Figure 8). Caco-2 cells are colon-like intestinal cells that differentiate spontaneously into
cells expressing markers characteristic of  small intestinal epithelium and are considered
the best cell line model for enterocytes (Van Beers et al. 1995). We measured the
expression of sucrase-isomaltase to confirm the differentiation of the cells. We found that
in addition to GATA-4 upregulation TGF-?1 was able to upregulate sucrase-isomaltase,
thus inducing differentiation (Figure 8). TGF-? signaling in the intestinal epithelium
probably includes Smad proteins Smad2, Smad3 and Smad4, which were activated in
TGF-?1-stimulated cells (Figure 4 in study IV) (Belaguli et al. 2007). TGF-?1 is known to
halt proliferation and promote differentiation and migration (Hafez et al. 1992). It is
tempting to speculate that in IBD it exerts its function via GATA-4. Together, they could
promote tissue healing and prevent further destruction of the inflamed bowel mucosa.
2.3 GATA-4 in the regulation of epithelial cell turnover (IV)
Epithelial cell turnover is accelerated in the inflamed intestinal mucosa, and the rate of
apoptosis is increased. The Bcl family of proteins, comprising both proapoptotic (e.g.
Bax) and antiapoptotic (e.g. Bcl-2) factors, orchestrates apoptosis in mammalian cells. The
antiapoptotic Bcl-2 protein is regulated by GATA-4 in the heart (Kobayashi et al. 2006)
and tumors of the gonads (Kyronlahti et al. 2008). In cardiomyocytes, Bcl-2 and GATA-4
have been shown to protect the cells from premature apoptosis induced by cardiotoxic
drugs (Aries et al. 2004). Moreover, rodent cardiomyocytes lacking GATA-4 protein are
prone to hyperglycemia-induced injury in vitro (Kobayashi et al. 2007). We showed
upregulation of Bcl-2 in inflammatory bowel samples (Figure 5 in study IV) consistent
with earlier studies (Karamanolis et al. 2007). We demonstrated for the first time a
correlation between the upregulation of Bcl-2 and enhanced GATA-4 expression in the
large bowel mucosa, suggesting that GATA-4 upregulates Bcl-2 in the intestine, probably
to protect the mucosa from inflammation-induced apoptosis (Table 9). It would be
interesting to determine whether GATA-4 and Bcl-2, similarly to already demonstrated in
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the heart, could protect the intestinal epithelium from epithelium-destructive drugs such as
the chemotherapeutic agents used in severe IBD and cancer therapies.
Table 9. Correlation between GATA-4/6 expression and TGF-? signaling, Indian Hedgehog,
Bcl-2, and Ki-67 in diseases of the distal gut.
Tissue GATA-4 GATA-6 TGF-?1 Smad3 Smad4 Ihh Bcl-2 Ki-67
Inflammation
Crohn’s disease + ++ ++ ++ ++ + ++ ++
Ulcerative colitis +/++ ++ ++ ++ ++ + ++ ++
Lymphocytic
colitis*
++ ++ ++ ++ ++ + ++ ++
Benign neoplasias
Colon adenoma - ++ ND ND ND ++ ND ND
Malignant tumors
Carcinoid tumor - +/++ ++ ND ND ND ND ND
Goblet cell
carcinoid
- ++ ND ND ND ND ND ND
Colon carcinoma -/+ + ND ND ND - ND ND
- no expression, + expression in single cells or small areas, ++ expression in large areas
Abbreviations: TGF, transforming growth factor; Ihh, Indian Hedgehog; ND, not determined
*A bowel disorder characterized by nonspecific lymphocytic mucosal inflammation with
aggregates of lymphatic cells.
3 GATA transcription factors in tumors of the digestive system
3.1 GATA-4 and GATA-6 in benign gastrointestinal neoplasias (III, V)
GATA-4, GATA-6, and its possible downstream target Ihh were analyzed in benign
gastrointestinal neoplasias (Table 2 in study III). Each of these factors was upregulated in
Barrett’s esophagus as well as in intestinal metaplasia of the stomach. Both neoplasias are
considered precancerous (Spechler and Goyal 1986, Correa and Houghton 2007).
Furthermore, neuroendocrine cell hyperplasia of the stomach was positive for GATA-4
and GATA-6 (Figure 4 in study III). This lesion often results from hypergastrinemia
linked to severe atrophic gastritis, leading to overstimulation of neuroendocrine cells. In
colon adenomas, GATA-6 expression was upregulated in high-grade dysplasias (Table 4
in study III).
3.2 Differential GATA expression during intestinal carcinogenesis (III, V)
GATA factors downregulate a histamine-synthesizing enzyme HDC (Watson et al. 2002),
which is stimulated by gastrin in neuroendocrine tissues and is increased in
neuroendocrine neoplasias. Some studies have reported GATA-4 and GATA-6 in the
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neuroendocrine cells of the murine gastrointestinal tract. In humans, we could not detect
GATA-4 or GATA-6 in normal gastrointestinal neuroendocrine cells. Endocrine cell
hyperplasia may proceed to a neuroendocrine tumor. Although GATA-6 was absent from
normal neuroendocrine cells (Figure 3 in study III), it was present in both neuroendocrine
hyperplasia (Figure 4 in study III) and carcinoid tumors (Figure 11). It is noteworthy that
while GATA-4 was expressed in neuroendocrine cell hyperplasia, it was downregulated in
tumors (Figure 11). In view of these results, we conclude that GATA-6 could promote
malignant and invasive growth in gastrointestinal neuroendocrine neoplasms.
Figure 11. GATA-6 is expressed in malignant intestinal tumors.
GATA-6 was detected in malignant carcinoid tumors and colon adenocarcinomas. The
immunoreactivity for GATA-6 was intense in the tumor edges or the stromal invasions
contradicting its almost undetectable expression in the tumor centres. GATA-4 was not detected in
malignant intestinal tumors. However, in 3 out of 6 colon cancer samples subjected to Northern
blot, a product of the size of GATA-4 was detected. Previously, we did not detect GATA-4 in the
tumor tissue itself but rather in the adjacent normal tissue often characterized by nonspecific
inflammation. Many tumors have also reported to produce large amounts of TGF-?.
The interesting pattern of GATA-6 positivity at tumor edges also manifested in colon
carcinomas. GATA-6, which showed modest expression in dysplastic lesions of the colon,
was remarkably intense in the border regions of tumors. Furthermore, in some samples
(n=5), stromal invasions showed robust nuclear positivity for GATA-6. The
possible GATA-6 downstream target Ihh, which was abundantly expressed in intestinal
adenomas, was downregulated in colon adenocarcinoma. GATA-6 is suggested to have
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both tumor-suppressive and -promotional action. It arrests the cell cycle in the G1 phase
by inducing CKI p21 in vitro (Figure 4) (Perlman et al. 1998, Setogawa et al. 2006).
However, it is also indicated in the inhibition of apoptosis and the induction of malignant
cell growth (Shureiqi et al. 2002). In the esophagus, it is proposed to indicate epithelial
transformation from a normal state to malignancy (Kimchi et al. 2005). Considering these
results, we suggest that GATA-6 serves as a tumor promoter with a proinvasive role in
carcinogenesis.
GATA-4 may meet posttranslational modifications, such as sumoylation, which
potentiates the transcriptional activity of GATA-4 in cardiac cells (Wang et al. 2004). In
cancers, contrarily, GATA-4 is reported to become silenced due to hypoacetylation of the
histones in ovarian cancers (Caslini et al. 2006). In gastrointestinal tumors, GATA-4, but
not GATA-6, is suggested to be inactivated by methylation (Derks et al. 2006, Guo et al.
2006). Furthermore, inactivating mutations of TGF-? signaling components are identified
at the adenoma to carcinoma transition (Pardali and Moustakas 2007). GATA-4 is shown
to have an inhibitory effect on GATA-6 (Morrisey et al. 1998), which promotes tumor
growth. We suggest that, in contrast to GATA-6, GATA-4 maintains the normal tissue
architecture and inhibits tumor malignancy in the gastrointestinal mucosa. Inactivating
GATA-4 may lead to impaired tissue growth and carcinogenesis.
3.3 Important role for GATA-4 in hepatic tumorigenesis (V)
Hepatoblastoma is an aggressive pediatric tumor of the liver. Extremely undifferentiated
hepatic tumor cells are characteristic of its histology. GATA-4 and GATA-6 are expressed
in fetal liver consisting of hepatocyte progenitors (Figure 12) (Dame et al. 2004). GATA-4
is considered fundamental for the development of the liver. It is able to prepare the
chromatin for further binding by opening the chromatin structure through its own binding
during the early endodermal development (Cirillo et al. 2002). In the adult liver, both
GATA-4 and GATA-6 are restricted to cells other than hepatocytes (unpublished results)
(Dame et al. 2004). In our study, GATA-4 was strongly expressed in hepatoblastomas. In
HCC, GATA-4 was confined to Kuppfer cells (Figure 12). FOG-1 protein was expressed
concomitantly with GATA-4, but it was mainly detected in the cytoplasm of the nodules
of hepatoblastoma (Table 10).
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Table 10. Protein expressions of GATA-4 and GATA-6, and the cofactors FOG-1 and FOG-2 in
different liver tumors.
No. Tumor type Age GATA-4 GATA-6 FOG1 EPO
Hepatoblastoma
1 Fetal epithelial 0.2 ++ - ++ ++
2 Fetal epithelial 0.9 + - + +
3 Fetal epithelial 1.1 ++ - ++ ++
4 Mixed epithelial mesenchymal 1.9 - - + -
5 Mixed epithelial mesenchymal 2.5 - - + ++
6 Fetal epithelial 4.0 - - + +
7 With features of HCC 4.1 + - - ++
8 Fetal epithelial, HCC 4.5 ++ - ++ ++
9 Fetal epithelial 4.8 ++ - ++ ++
10 Embryonal 5.3 ++ - ++ ++
11 Embryonal, residive 6.8 - - - -
12 Metastatic hepatoblastoma 8.8 ++ + - ++
13 Fetal epithelial 9.1 ++ - - ++
14 Fetal epithelial, residive 12 - - - -
Hepatocellular carcinoma
15 Biliary cirrhosis 2.0 ++ - ++ ++
16 Fibrolamellar 8.0 + - + -
17 Fibrolamellar 13 - - + -
18 Bright cells, hemosiderosis 14 - - - -
19 Fibrolamellar 14 + - + +
20 Bright cells 14 - - - -
21 Cirrhosis 57 - - - -
22 Low differentiation, regenerative nodi 59 - - - -
23 High differentiation 62 - - - -
24 High differentiation 63 - - - -
25 High differentiation 74 - - - -
26 Low differentiation, fatty liver 75 - - - -
27 High differentiation - - - - -
 - no expression, + expression in single cells or small areas, ++ expression in large areas
Tyrosinemia type I is a pediatric metabolic disorder with hepatic lesions. Histologic
analysis reveals liver cirrhosis, regenerative nodules in the liver parenchyma, and,
occasionally, dysplasia or HCC (Ashorn et al. 2006). We detected GATA-4 along with
Epo in the regenerative nodules, but not in adenoma or developing cancer (Figure 12).
GATA-6 was positive in the hyperproliferative bile ducts of the mesenchyme. In addition,
both GATA-4 and GATA-6 were detected in the periportal tissue of cells morphologically
resembling macrophages. FOG-2, which is generally considered the GATA-4 cofactor,
showed no nuclear positivity, as also detected in hepatic tumors.
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Figure 12. GATA-4 and Epo expression in hepatic tumors
Concomitant GATA-4 and Epo upregulation was detected in fetal parenchyma, hepatoblastoma
(HB) as well as in the regenerative nodules of the hereditary tyrosinemia type I (HT I). In contrats,
the parenchyma of the adult tissue (in inset) and hepatocellular carcinoma (HCC) were devoid of
GATA-4 similarly to Epo (normal tissue not shown). Scale bar is for 200 ?m. In Western blot, all
5 samples of hepatoblastoma expressed GATA-4, while the other of the HCC samples, as well as
the normal control, was devoid of GATA-4.
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One of the most remarkable findings in our study was the coexpression of Epo with
GATA-4 in hepatoblastomas (Figure 13). Furthermore, elevated levels of Epo were
detected in the serum samples of the respective tumor patients (data not shown). Of all
GATA family members, GATA-4 is the most potent regulator of the Epo gene in cell
cultures (Dame et al. 2004). Considering the similarities of the expressions of GATA-4
and Epo in hepatoblastomas and regenerative nodules of cirrhotic pediatric liver, we
suggest that Epo is upregulated by GATA-4 in pediatric hepatic tumors.
Figure 13. Upregulation of GATA-4 and Epo in tumors of a primitive hepatic cell lineage.
Modified from Sell and Leffert (2008).
Hepatoblastoma has features of embryonal and fetal liver cells and tissue. In contrast to
hepatocellular carcinoma, hepatoblastomas respond rather well to chemotherapy. Yet
concomitant surgery is often indicated due to large tumor size at diagnosis. AFP has been
used as a serum marker for hepatoblastoma. However, serum AFP is elevated in other
hepatic disorders such as inflammation and cirrhosis. Therefore, a surplus of AFP, GATA-
4 could serve as a histological marker for malignant pediatric tumors. While GATA-4 can
only be detected from tissue samples, its suggested downstream factor Epo could be
measured from serum samples, which would ease the diagnostics considerably. Together,
the detection of these factors from serum samples and tissue biopsies could supplement
other diagnostic methods and serve as future targets for new therapeutic innovations.
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CONCLUSIONS AND FUTURE PERSPECTIVES
1. The present study demonstrates distinct cell- and tissue-specific expression patterns for
transcription factors GATA-4, GATA-5, and GATA-6 in the developing and mature
human and murine gastrointestinal tract and liver. GATA factors cooperate with HNF-1?
in the regulation of intestine- and liver-specific Fabpl. GATA factors are also able to
cooperate with each other, increasing the upregulatory effect on intestinal genes. In
addition, GATA-5 appears to play a specific role in the intestinal villous maturation of
suckling mice.
2. GATA-4 is associated with the TGF-? signaling pathway in intestinal inflammation.
We conclude that it is upregulated by TGF-?1, which enhances tissue regeneration, cell
differentiation and migration. We also detected a positive correlation between GATA-4
and the antiapoptotic Bcl-2. We propose that GATA-4 could act as a protective
transcription factor that regulates genes important for the maintenance of normal epithelial
architecture. Nevertheless, further functional studies should be performed to verify these
assumptions.
3. As GATA-4 is indicated in the inflamed intestine and in some benign gastrointestinal
neoplasias and neuroendocrine hyperplasia, but not in malignant tumors, we conclude that
GATA-4 could serve as a marker for the transition between benign neoplasms and
malignant tumors. However, more tumor data are needed to verify these observations. In
contrast to GATA-4, GATA-6 might play a role in the invasion of tumors. Considering the
strong associations with tumorigenesis, the therapeutic possibilities of both GATA-4 and
GATA-6 should be assessed thoroughly.
4. GATA-4 is expressed in hepatoblastomas as well as in some pediatric hepatocellular
carcinomas and regenerative hepatic nodules of tyrosinemia patients. However, GATA-4
is not detected in adult tumors or in hepatic regeneration. In view of this, we suggest that
GATA-4 is associated with pediatric tumors derived from hepatic stem cells that are
postulated to be of a more potent type than those found in adults. GATA cofactor FOG-1
and the GATA-regulated Epo are expressed concomitantly with GATA-4. Furthermore,
the level of Epo expression is elevated in the sera of patients with hepatoblastoma. Our
findings emphasize the importance of GATA-4 in pediatric tumor development. Together
with Epo, as both a histologic and serum marker, GATA-4 could supplement the current
diagnostic markers used in detection and surveillance of pediatric tumors.
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Clinical significance
Patients with chronic gastrointestinal inflammation or benign neoplasias, such as IBD or
Barrett’s esophagus, need regular follow-up. The histologic distinction between benign
and malignant tumors is often difficult. New tissue markers for indicating the tumor
transition to malignancy are required. Furthermore, elucidation of the pathogenesis is
important for devising more targeted therapies. Tissue-specific gene silencing has recently
been commonly discussed as a new therapeutic method for cancer. It would be interesting
to investigate whether silencing of the putative tumor promoter gene GATA-6 would
prevent malignant transformation of e.g. neuroendocrine cell neoplasias or intestinal
adenomas. The possibility of GATA-4 as a novel therapeutic target for the treatment of
pediatric hepatic tumors as well as its use as a tumor marker along with Epo should also
be thoroughly scrutinized.
In summary, our study demonstrates that GATA factors play important roles in
gastrointestinal and hepatic tumor biology.
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